[{"PMID": 9890894, "id": 9, "text": "These results suggest that a complex of Ig module II and heparan sulfate is the base common active core of the FGFR ectodomain and that flanking structural domains modify FGF affinity and determine specificity.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [65, 72], "name": "sulfate", "tok_span": [13, 14], "new_tok_span": [13, 14]}, {"ent_type": "GENE", "char_span": [40, 52], "name": "Ig module II", "tok_span": [7, 10], "new_tok_span": [7, 10]}, {"ent_type": "GENE", "char_span": [111, 126], "name": "FGFR ectodomain", "tok_span": [22, 27], "new_tok_span": [25, 30]}, {"ent_type": "GENE", "char_span": [171, 174], "name": "FGF", "tok_span": [33, 34], "new_tok_span": [41, 42]}], "relation_list": [{"subject": "sulfate", "sbj_char_span": [65, 72], "object": "Ig module II", "obj_char_span": [40, 52], "rel_type": "regulator", "sbj_tok_span": [13, 14], "obj_tok_span": [7, 10], "new_sbj_tok_span": [13, 14], "new_obj_tok_span": [7, 10]}], "umls_entity_list": [{"mention": "FGFR", "char_span": [111, 115], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [22, 24], "new_tok_span": [25, 27]}, {"mention": "FGF", "char_span": [111, 114], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [22, 23], "new_tok_span": [25, 26]}, {"mention": "FGF", "char_span": [171, 174], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [33, 34], "new_tok_span": [41, 42]}, {"mention": "FGF", "char_span": [111, 114], "sem_type": "Gene or Genome", "tok_span": [22, 23], "new_tok_span": [25, 26]}, {"mention": "FGF", "char_span": [171, 174], "sem_type": "Gene or Genome", "tok_span": [33, 34], "new_tok_span": [41, 42]}], "new_text": "These results suggest that a complex of Ig module II and heparan sulfate is the base common active core of the <START=Amino Acid, Peptide, or Protein> <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> FGF <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome>R <END=Amino Acid, Peptide, or Protein> ectodomain and that flanking structural domains modify <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> FGF <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> affinity and determine specificity."}, {"PMID": 10640321, "id": 2, "text": "Parenteral administration of selective agonists of the delta-opioid receptor (SB 227122), mu-opioid receptor (codeine and hydrocodone), and kappa-opioid receptor (BRL 52974) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [78, 87], "name": "SB 227122", "tok_span": [13, 16], "new_tok_span": [13, 16]}, {"ent_type": "CHEMICAL", "char_span": [110, 117], "name": "codeine", "tok_span": [23, 25], "new_tok_span": [24, 26]}, {"ent_type": "CHEMICAL", "char_span": [122, 133], "name": "hydrocodone", "tok_span": [26, 30], "new_tok_span": [29, 33]}, {"ent_type": "CHEMICAL", "char_span": [163, 172], "name": "BRL 52974", "tok_span": [38, 43], "new_tok_span": [43, 48]}, {"ent_type": "CHEMICAL", "char_span": [210, 221], "name": "citric acid", "tok_span": [50, 53], "new_tok_span": [57, 60]}, {"ent_type": "GENE", "char_span": [55, 76], "name": "delta-opioid receptor", "tok_span": [8, 12], "new_tok_span": [8, 12]}, {"ent_type": "GENE", "char_span": [90, 108], "name": "mu-opioid receptor", "tok_span": [18, 22], "new_tok_span": [18, 22]}, {"ent_type": "GENE", "char_span": [140, 161], "name": "kappa-opioid receptor", "tok_span": [33, 37], "new_tok_span": [37, 41]}], "relation_list": [{"subject": "SB 227122", "sbj_char_span": [78, 87], "object": "delta-opioid receptor", "obj_char_span": [55, 76], "rel_type": "agonist or antagonist", "sbj_tok_span": [13, 16], "obj_tok_span": [8, 12], "new_sbj_tok_span": [13, 16], "new_obj_tok_span": [8, 12]}, {"subject": "codeine", "sbj_char_span": [110, 117], "object": "mu-opioid receptor", "obj_char_span": [90, 108], "rel_type": "agonist or antagonist", "sbj_tok_span": [23, 25], "obj_tok_span": [18, 22], "new_sbj_tok_span": [24, 26], "new_obj_tok_span": [18, 22]}, {"subject": "hydrocodone", "sbj_char_span": [122, 133], "object": "mu-opioid receptor", "obj_char_span": [90, 108], "rel_type": "agonist or antagonist", "sbj_tok_span": [26, 30], "obj_tok_span": [18, 22], "new_sbj_tok_span": [29, 33], "new_obj_tok_span": [18, 22]}, {"subject": "BRL 52974", "sbj_char_span": [163, 172], "object": "kappa-opioid receptor", "obj_char_span": [140, 161], "rel_type": "agonist or antagonist", "sbj_tok_span": [38, 43], "obj_tok_span": [33, 37], "new_sbj_tok_span": [43, 48], "new_obj_tok_span": [37, 41]}], "umls_entity_list": [{"mention": "codeine", "char_span": [110, 117], "sem_type": "Pharmacologic Substance", "tok_span": [23, 25], "new_tok_span": [24, 26]}, {"mention": "hydrocodon", "char_span": [122, 132], "sem_type": "Pharmacologic Substance", "tok_span": [26, 29], "new_tok_span": [29, 32]}, {"mention": "BRL", "char_span": [163, 166], "sem_type": "Pharmacologic Substance", "tok_span": [38, 40], "new_tok_span": [43, 45]}, {"mention": "citric acid", "char_span": [210, 221], "sem_type": "Pharmacologic Substance", "tok_span": [50, 53], "new_tok_span": [57, 60]}], "new_text": "Parenteral administration of selective agonists of the delta - opioid receptor ( SB 227122 ), mu - opioid receptor ( <START=Pharmacologic Substance> codeine <END=Pharmacologic Substance> and <START=Pharmacologic Substance> hydrocodon <END=Pharmacologic Substance>e ), and kappa - opioid receptor ( <START=Pharmacologic Substance> BRL <END=Pharmacologic Substance> 52974 ) produced dose - related inhibition of <START=Pharmacologic Substance> citric acid <END=Pharmacologic Substance> - induced cough with ED ( 50 ) values of 7. 3, 5. 2, 5. 1, and 5. 3 mg / kg, respectively."}, {"PMID": 20615127, "id": 7, "text": "Consistent with the results of a computer analysis, the binding of R316C to triiodothyronine (T3) was significantly decreased to 38% that of the wild type.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [76, 92], "name": "triiodothyronine", "tok_span": [17, 22], "new_tok_span": [18, 23]}, {"ent_type": "CHEMICAL", "char_span": [94, 96], "name": "T3", "tok_span": [23, 25], "new_tok_span": [25, 27]}, {"ent_type": "GENE", "char_span": [67, 72], "name": "R316C", "tok_span": [12, 16], "new_tok_span": [12, 16]}], "relation_list": [{"subject": "triiodothyronine", "sbj_char_span": [76, 92], "object": "R316C", "obj_char_span": [67, 72], "rel_type": "regulator", "sbj_tok_span": [17, 22], "obj_tok_span": [12, 16], "new_sbj_tok_span": [18, 23], "new_obj_tok_span": [12, 16]}, {"subject": "T3", "sbj_char_span": [94, 96], "object": "R316C", "obj_char_span": [67, 72], "rel_type": "regulator", "sbj_tok_span": [23, 25], "obj_tok_span": [12, 16], "new_sbj_tok_span": [25, 27], "new_obj_tok_span": [12, 16]}], "umls_entity_list": [{"mention": "triiodothyronine", "char_span": [76, 92], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [17, 22], "new_tok_span": [18, 23]}], "new_text": "Consistent with the results of a computer analysis, the binding of R316C to <START=Amino Acid, Peptide, or Protein> triiodothyronine <END=Amino Acid, Peptide, or Protein> ( T3 ) was significantly decreased to 38 % that of the wild type."}, {"PMID": 9832994, "id": 3, "text": "Additional neuroendocrine experiments in a parallel group of rats revealed a dose-related increase in plasma prolactin and ACTH levels after i.v. mCPP, pointing to a general state of arousal in these mCPP-treated animals.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [146, 150], "name": "mCPP", "tok_span": [27, 30], "new_tok_span": [31, 34]}, {"ent_type": "CHEMICAL", "char_span": [200, 204], "name": "mCPP", "tok_span": [40, 43], "new_tok_span": [48, 51]}, {"ent_type": "GENE", "char_span": [102, 118], "name": "plasma prolactin", "tok_span": [16, 19], "new_tok_span": [16, 19]}, {"ent_type": "GENE", "char_span": [123, 127], "name": "ACTH", "tok_span": [20, 21], "new_tok_span": [22, 23]}], "relation_list": [{"subject": "mCPP", "sbj_char_span": [146, 150], "object": "plasma prolactin", "obj_char_span": [102, 118], "rel_type": "regulator", "sbj_tok_span": [27, 30], "obj_tok_span": [16, 19], "new_sbj_tok_span": [31, 34], "new_obj_tok_span": [16, 19]}, {"subject": "mCPP", "sbj_char_span": [146, 150], "object": "ACTH", "obj_char_span": [123, 127], "rel_type": "regulator", "sbj_tok_span": [27, 30], "obj_tok_span": [20, 21], "new_sbj_tok_span": [31, 34], "new_obj_tok_span": [22, 23]}], "umls_entity_list": [{"mention": "prolactin", "char_span": [109, 118], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [17, 19], "new_tok_span": [18, 20]}, {"mention": "mCPP", "char_span": [146, 150], "sem_type": "Pharmacologic Substance", "tok_span": [27, 30], "new_tok_span": [31, 34]}, {"mention": "mCPP", "char_span": [200, 204], "sem_type": "Pharmacologic Substance", "tok_span": [40, 43], "new_tok_span": [48, 51]}, {"mention": "mCPP", "char_span": [146, 150], "sem_type": "Organic Chemical", "tok_span": [27, 30], "new_tok_span": [31, 34]}, {"mention": "mCPP", "char_span": [200, 204], "sem_type": "Organic Chemical", "tok_span": [40, 43], "new_tok_span": [48, 51]}], "new_text": "Additional neuroendocrine experiments in a parallel group of rats revealed a dose - related increase in plasma <START=Amino Acid, Peptide, or Protein> prolactin <END=Amino Acid, Peptide, or Protein> and ACTH levels after i. v. <START=Pharmacologic Substance> <START=Organic Chemical> mCPP <END=Pharmacologic Substance> <END=Organic Chemical>, pointing to a general state of arousal in these <START=Pharmacologic Substance> <START=Organic Chemical> mCPP <END=Pharmacologic Substance> <END=Organic Chemical> - treated animals."}, {"PMID": 23493568, "id": 4, "text": "To evaluate the role of XBP1 in α-cells, we created complementary in vivo (α-cell specific XBP1 knockout (αXBPKO) mice) and in vitro (stable XBP1 knock down α-cell line, αXBPKD) models. αXBPKO mice exhibited glucose intolerance, mild insulin resistance and an inability to suppress glucagon secretion following glucose stimulation. αXBPKD cells exhibited activation of IRE1, an upstream activator of XBP1, leading to phosphorylation of JNK. Interestingly, insulin treatment of αXBPKD cells reduced tyrosine phosphorylation of IRS-1 (pY(896)), and phosphorylation of Akt, while enhancing serine phosphorylation (pS(307)) of IRS-1.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [498, 506], "name": "tyrosine", "tok_span": [119, 120], "new_tok_span": [141, 142]}, {"ent_type": "CHEMICAL", "char_span": [587, 593], "name": "serine", "tok_span": [141, 142], "new_tok_span": [165, 166]}, {"ent_type": "CHEMICAL", "char_span": [208, 215], "name": "glucose", "tok_span": [63, 64], "new_tok_span": [75, 76]}, {"ent_type": "CHEMICAL", "char_span": [311, 318], "name": "glucose", "tok_span": [79, 80], "new_tok_span": [91, 92]}, {"ent_type": "GENE", "char_span": [526, 531], "name": "IRS-1", "tok_span": [122, 125], "new_tok_span": [145, 148]}, {"ent_type": "GENE", "char_span": [566, 569], "name": "Akt", "tok_span": [137, 138], "new_tok_span": [161, 162]}, {"ent_type": "GENE", "char_span": [623, 628], "name": "IRS-1", "tok_span": [152, 155], "new_tok_span": [181, 184]}, {"ent_type": "GENE", "char_span": [24, 28], "name": "XBP1", "tok_span": [5, 8], "new_tok_span": [7, 10]}, {"ent_type": "GENE", "char_span": [91, 95], "name": "XBP1", "tok_span": [23, 26], "new_tok_span": [29, 32]}, {"ent_type": "GENE", "char_span": [107, 110], "name": "XBP", "tok_span": [29, 31], "new_tok_span": [37, 39]}, {"ent_type": "GENE", "char_span": [141, 145], "name": "XBP1", "tok_span": [40, 43], "new_tok_span": [50, 53]}, {"ent_type": "GENE", "char_span": [171, 174], "name": "XBP", "tok_span": [51, 53], "new_tok_span": [63, 65]}, {"ent_type": "GENE", "char_span": [187, 190], "name": "XBP", "tok_span": [58, 60], "new_tok_span": [70, 72]}, {"ent_type": "GENE", "char_span": [234, 241], "name": "insulin", "tok_span": [69, 70], "new_tok_span": [81, 82]}, {"ent_type": "GENE", "char_span": [282, 290], "name": "glucagon", "tok_span": [76, 77], "new_tok_span": [88, 89]}, {"ent_type": "GENE", "char_span": [333, 336], "name": "XBP", "tok_span": [83, 85], "new_tok_span": [95, 97]}, {"ent_type": "GENE", "char_span": [369, 373], "name": "IRE1", "tok_span": [90, 93], "new_tok_span": [103, 106]}, {"ent_type": "GENE", "char_span": [400, 404], "name": "XBP1", "tok_span": [98, 101], "new_tok_span": [118, 121]}, {"ent_type": "GENE", "char_span": [436, 439], "name": "JNK", "tok_span": [106, 107], "new_tok_span": [128, 129]}, {"ent_type": "GENE", "char_span": [456, 463], "name": "insulin", "tok_span": [110, 111], "new_tok_span": [132, 133]}, {"ent_type": "GENE", "char_span": [478, 481], "name": "XBP", "tok_span": [114, 116], "new_tok_span": [136, 138]}], "relation_list": [{"subject": "tyrosine", "sbj_char_span": [498, 506], "object": "IRS-1", "obj_char_span": [526, 531], "rel_type": "part of", "sbj_tok_span": [119, 120], "obj_tok_span": [122, 125], "new_sbj_tok_span": [141, 142], "new_obj_tok_span": [145, 148]}, {"subject": "serine", "sbj_char_span": [587, 593], "object": "IRS-1", "obj_char_span": [623, 628], "rel_type": "part of", "sbj_tok_span": [141, 142], "obj_tok_span": [152, 155], "new_sbj_tok_span": [165, 166], "new_obj_tok_span": [181, 184]}], "umls_entity_list": [{"mention": "XBP1", "char_span": [24, 28], "sem_type": "Gene or Genome", "tok_span": [5, 8], "new_tok_span": [7, 10]}, {"mention": "XBP1", "char_span": [91, 95], "sem_type": "Gene or Genome", "tok_span": [23, 26], "new_tok_span": [29, 32]}, {"mention": "XBP1", "char_span": [141, 145], "sem_type": "Gene or Genome", "tok_span": [40, 43], "new_tok_span": [50, 53]}, {"mention": "XBP1", "char_span": [400, 404], "sem_type": "Gene or Genome", "tok_span": [98, 101], "new_tok_span": [118, 121]}, {"mention": "XBP1", "char_span": [24, 28], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [5, 8], "new_tok_span": [7, 10]}, {"mention": "XBP1", "char_span": [91, 95], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [23, 26], "new_tok_span": [29, 32]}, {"mention": "XBP1", "char_span": [141, 145], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [40, 43], "new_tok_span": [50, 53]}, {"mention": "XBP1", "char_span": [400, 404], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [98, 101], "new_tok_span": [118, 121]}, {"mention": "IRE1", "char_span": [369, 373], "sem_type": "Gene or Genome", "tok_span": [90, 93], "new_tok_span": [103, 106]}, {"mention": "IRS-1", "char_span": [526, 531], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [122, 125], "new_tok_span": [145, 148]}, {"mention": "IRS-1", "char_span": [623, 628], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [152, 155], "new_tok_span": [181, 184]}, {"mention": "ps", "char_span": [379, 381], "sem_type": "Organic Chemical", "tok_span": [95, 96], "new_tok_span": [111, 112]}, {"mention": "pS", "char_span": [611, 613], "sem_type": "Organic Chemical", "tok_span": [144, 146], "new_tok_span": [170, 172]}, {"mention": "ps", "char_span": [379, 381], "sem_type": "Gene or Genome", "tok_span": [95, 96], "new_tok_span": [111, 112]}, {"mention": "pS", "char_span": [611, 613], "sem_type": "Gene or Genome", "tok_span": [144, 146], "new_tok_span": [170, 172]}], "new_text": "To evaluate the role of <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> XBP1 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> in α - cells, we created complementary in vivo ( α - cell specific <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> XBP1 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> knockout ( αXBPKO ) mice ) and in vitro ( stable <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> XBP1 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> knock down α - cell line, αXBPKD ) models. αXBPKO mice exhibited glucose intolerance, mild insulin resistance and an inability to suppress glucagon secretion following glucose stimulation. αXBPKD cells exhibited activation of <START=Gene or Genome> IRE1 <END=Gene or Genome>, an <START=Organic Chemical> <START=Gene or Genome> upstream <END=Organic Chemical> <END=Gene or Genome> activator of <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> XBP1 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein>, leading to phosphorylation of JNK. Interestingly, insulin treatment of αXBPKD cells reduced tyrosine phosphorylation of <START=Amino Acid, Peptide, or Protein> IRS - 1 <END=Amino Acid, Peptide, or Protein> ( pY ( 896 ) ), and phosphorylation of Akt, while enhancing serine phosphorylation ( <START=Organic Chemical> <START=Gene or Genome> pS <END=Organic Chemical> <END=Gene or Genome> ( 307 ) ) of <START=Amino Acid, Peptide, or Protein> IRS - 1 <END=Amino Acid, Peptide, or Protein>."}, {"PMID": 9990013, "id": 1, "text": "The ATP-sensitive potassium (KATP) channels in pancreatic beta cells are critical in the regulation of glucose-induced insulin secretion.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [103, 110], "name": "glucose", "tok_span": [20, 21], "new_tok_span": [25, 26]}, {"ent_type": "CHEMICAL", "char_span": [18, 27], "name": "potassium", "tok_span": [4, 5], "new_tok_span": [5, 6]}, {"ent_type": "CHEMICAL", "char_span": [4, 7], "name": "ATP", "tok_span": [1, 2], "new_tok_span": [1, 2]}, {"ent_type": "GENE", "char_span": [119, 126], "name": "insulin", "tok_span": [23, 24], "new_tok_span": [29, 30]}, {"ent_type": "GENE", "char_span": [4, 43], "name": "ATP-sensitive potassium (KATP) channels", "tok_span": [1, 10], "new_tok_span": [1, 10]}], "relation_list": [{"subject": "glucose", "sbj_char_span": [103, 110], "object": "insulin", "obj_char_span": [119, 126], "rel_type": "regulator", "sbj_tok_span": [20, 21], "obj_tok_span": [23, 24], "new_sbj_tok_span": [25, 26], "new_obj_tok_span": [29, 30]}], "umls_entity_list": [{"mention": "potassium", "char_span": [18, 27], "sem_type": "Pharmacologic Substance", "tok_span": [4, 5], "new_tok_span": [5, 6]}, {"mention": "KATP", "char_span": [29, 33], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [6, 8], "new_tok_span": [9, 11]}, {"mention": "glucose", "char_span": [103, 110], "sem_type": "Pharmacologic Substance", "tok_span": [20, 21], "new_tok_span": [25, 26]}], "new_text": "The ATP - sensitive <START=Pharmacologic Substance> potassium <END=Pharmacologic Substance> ( <START=Amino Acid, Peptide, or Protein> KATP <END=Amino Acid, Peptide, or Protein> ) channels in pancreatic beta cells are critical in the regulation of <START=Pharmacologic Substance> glucose <END=Pharmacologic Substance> - induced insulin secretion."}, {"PMID": 17040106, "id": 3, "text": "On the basis of our findings with structurally similar arylhydroxylamine metabolites of therapeutic drugs, we hypothesized that the reductive detoxification of arylhydroxylamine carcinogens was catalyzed by NADH cytochrome b5 reductase (b5R) and cytochrome b5 (cyt b5).", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [55, 72], "name": "arylhydroxylamine", "tok_span": [9, 13], "new_tok_span": [9, 13]}, {"ent_type": "CHEMICAL", "char_span": [160, 177], "name": "arylhydroxylamine", "tok_span": [27, 31], "new_tok_span": [29, 33]}, {"ent_type": "CHEMICAL", "char_span": [207, 211], "name": "NADH", "tok_span": [36, 37], "new_tok_span": [38, 39]}, {"ent_type": "GENE", "char_span": [207, 235], "name": "NADH cytochrome b5 reductase", "tok_span": [36, 41], "new_tok_span": [38, 43]}, {"ent_type": "GENE", "char_span": [237, 240], "name": "b5R", "tok_span": [42, 45], "new_tok_span": [46, 49]}, {"ent_type": "GENE", "char_span": [246, 259], "name": "cytochrome b5", "tok_span": [47, 50], "new_tok_span": [51, 54]}, {"ent_type": "GENE", "char_span": [261, 267], "name": "cyt b5", "tok_span": [51, 54], "new_tok_span": [55, 58]}], "relation_list": [{"subject": "arylhydroxylamine", "sbj_char_span": [160, 177], "object": "NADH cytochrome b5 reductase", "obj_char_span": [207, 235], "rel_type": "product or substrate", "sbj_tok_span": [27, 31], "obj_tok_span": [36, 41], "new_sbj_tok_span": [29, 33], "new_obj_tok_span": [38, 43]}, {"subject": "arylhydroxylamine", "sbj_char_span": [160, 177], "object": "b5R", "obj_char_span": [237, 240], "rel_type": "product or substrate", "sbj_tok_span": [27, 31], "obj_tok_span": [42, 45], "new_sbj_tok_span": [29, 33], "new_obj_tok_span": [46, 49]}, {"subject": "arylhydroxylamine", "sbj_char_span": [160, 177], "object": "cytochrome b5", "obj_char_span": [246, 259], "rel_type": "product or substrate", "sbj_tok_span": [27, 31], "obj_tok_span": [47, 50], "new_sbj_tok_span": [29, 33], "new_obj_tok_span": [51, 54]}, {"subject": "arylhydroxylamine", "sbj_char_span": [160, 177], "object": "cyt b5", "obj_char_span": [261, 267], "rel_type": "product or substrate", "sbj_tok_span": [27, 31], "obj_tok_span": [51, 54], "new_sbj_tok_span": [29, 33], "new_obj_tok_span": [55, 58]}], "umls_entity_list": [{"mention": "drugs", "char_span": [100, 105], "sem_type": "Pharmacologic Substance", "tok_span": [16, 17], "new_tok_span": [17, 18]}, {"mention": "cytochrome b5 reductase", "char_span": [212, 235], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [37, 41], "new_tok_span": [40, 44]}], "new_text": "On the basis of our findings with structurally similar arylhydroxylamine metabolites of therapeutic <START=Pharmacologic Substance> drugs <END=Pharmacologic Substance>, we hypothesized that the reductive detoxification of arylhydroxylamine carcinogens was catalyzed by NADH <START=Amino Acid, Peptide, or Protein> cytochrome b5 reductase <END=Amino Acid, Peptide, or Protein> ( b5R ) and cytochrome b5 ( cyt b5 )."}, {"PMID": 12827214, "id": 5, "text": "On the other hand, ligands for the renal Na(+)-transporter (amiloride and triamterene) and for imidazoline recognition sites (guanabenz, guanfacine and agmatine) displaced the binding of [(3)H]prazosin to phentolamine-insensitive sites at micromolar concentrations.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [41, 46], "name": "Na(+)", "tok_span": [9, 13], "new_tok_span": [9, 13]}, {"ent_type": "CHEMICAL", "char_span": [60, 69], "name": "amiloride", "tok_span": [16, 20], "new_tok_span": [16, 20]}, {"ent_type": "CHEMICAL", "char_span": [74, 85], "name": "triamterene", "tok_span": [21, 25], "new_tok_span": [21, 25]}, {"ent_type": "CHEMICAL", "char_span": [95, 106], "name": "imidazoline", "tok_span": [28, 32], "new_tok_span": [29, 33]}, {"ent_type": "CHEMICAL", "char_span": [126, 135], "name": "guanabenz", "tok_span": [35, 38], "new_tok_span": [38, 41]}, {"ent_type": "CHEMICAL", "char_span": [137, 147], "name": "guanfacine", "tok_span": [39, 42], "new_tok_span": [44, 47]}, {"ent_type": "CHEMICAL", "char_span": [152, 160], "name": "agmatine", "tok_span": [43, 46], "new_tok_span": [49, 52]}, {"ent_type": "CHEMICAL", "char_span": [187, 201], "name": "[(3)H]prazosin", "tok_span": [51, 60], "new_tok_span": [57, 66]}, {"ent_type": "CHEMICAL", "char_span": [205, 217], "name": "phentolamine", "tok_span": [61, 64], "new_tok_span": [70, 73]}, {"ent_type": "GENE", "char_span": [41, 58], "name": "Na(+)-transporter", "tok_span": [9, 15], "new_tok_span": [9, 15]}], "relation_list": [{"subject": "amiloride", "sbj_char_span": [60, 69], "object": "Na(+)-transporter", "obj_char_span": [41, 58], "rel_type": "regulator", "sbj_tok_span": [16, 20], "obj_tok_span": [9, 15], "new_sbj_tok_span": [16, 20], "new_obj_tok_span": [9, 15]}, {"subject": "triamterene", "sbj_char_span": [74, 85], "object": "Na(+)-transporter", "obj_char_span": [41, 58], "rel_type": "regulator", "sbj_tok_span": [21, 25], "obj_tok_span": [9, 15], "new_sbj_tok_span": [21, 25], "new_obj_tok_span": [9, 15]}], "umls_entity_list": [{"mention": "imidazoline", "char_span": [95, 106], "sem_type": "Organic Chemical", "tok_span": [28, 32], "new_tok_span": [29, 33]}, {"mention": "guanabenz", "char_span": [126, 135], "sem_type": "Pharmacologic Substance", "tok_span": [35, 38], "new_tok_span": [38, 41]}, {"mention": "guanfacine", "char_span": [137, 147], "sem_type": "Pharmacologic Substance", "tok_span": [39, 42], "new_tok_span": [44, 47]}, {"mention": "prazosin", "char_span": [193, 201], "sem_type": "Pharmacologic Substance", "tok_span": [57, 60], "new_tok_span": [64, 67]}, {"mention": "phentolamine", "char_span": [205, 217], "sem_type": "Pharmacologic Substance", "tok_span": [61, 64], "new_tok_span": [70, 73]}], "new_text": "On the other hand, ligands for the renal Na ( + ) - transporter ( amiloride and triamterene ) and for <START=Organic Chemical> imidazoline <END=Organic Chemical> recognition sites ( <START=Pharmacologic Substance> guanabenz <END=Pharmacologic Substance>, <START=Pharmacologic Substance> guanfacine <END=Pharmacologic Substance> and agmatine ) displaced the binding of [ ( 3 ) H ] <START=Pharmacologic Substance> prazosin <END=Pharmacologic Substance> to <START=Pharmacologic Substance> phentolamine <END=Pharmacologic Substance> - insensitive sites at micromolar concentrations."}, {"PMID": 8384716, "id": 4, "text": "Within the conserved transmembrane domains, the sequences exhibit approximately 52%, 59%, 65%, and 68% amino acid identity with the known rat 5-HT1A, rat 5-HT1B, rat 5-HT1D, and human 5-HT1E receptors, respectively.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [103, 113], "name": "amino acid", "tok_span": [22, 24], "new_tok_span": [23, 25]}, {"ent_type": "GENE", "char_span": [138, 148], "name": "rat 5-HT1A", "tok_span": [28, 34], "new_tok_span": [30, 36]}, {"ent_type": "GENE", "char_span": [150, 160], "name": "rat 5-HT1B", "tok_span": [35, 41], "new_tok_span": [37, 43]}, {"ent_type": "GENE", "char_span": [162, 172], "name": "rat 5-HT1D", "tok_span": [42, 48], "new_tok_span": [44, 50]}, {"ent_type": "GENE", "char_span": [178, 190], "name": "human 5-HT1E", "tok_span": [50, 56], "new_tok_span": [52, 58]}], "relation_list": [{"subject": "amino acid", "sbj_char_span": [103, 113], "object": "rat 5-HT1A", "obj_char_span": [138, 148], "rel_type": "part of", "sbj_tok_span": [22, 24], "obj_tok_span": [28, 34], "new_sbj_tok_span": [23, 25], "new_obj_tok_span": [30, 36]}, {"subject": "amino acid", "sbj_char_span": [103, 113], "object": "rat 5-HT1B", "obj_char_span": [150, 160], "rel_type": "part of", "sbj_tok_span": [22, 24], "obj_tok_span": [35, 41], "new_sbj_tok_span": [23, 25], "new_obj_tok_span": [37, 43]}, {"subject": "amino acid", "sbj_char_span": [103, 113], "object": "rat 5-HT1D", "obj_char_span": [162, 172], "rel_type": "part of", "sbj_tok_span": [22, 24], "obj_tok_span": [42, 48], "new_sbj_tok_span": [23, 25], "new_obj_tok_span": [44, 50]}, {"subject": "amino acid", "sbj_char_span": [103, 113], "object": "human 5-HT1E", "obj_char_span": [178, 190], "rel_type": "part of", "sbj_tok_span": [22, 24], "obj_tok_span": [50, 56], "new_sbj_tok_span": [23, 25], "new_obj_tok_span": [52, 58]}], "umls_entity_list": [{"mention": "amino acid", "char_span": [103, 113], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [22, 24], "new_tok_span": [23, 25]}], "new_text": "Within the conserved transmembrane domains, the sequences exhibit approximately 52 %, 59 %, 65 %, and 68 % <START=Amino Acid, Peptide, or Protein> amino acid <END=Amino Acid, Peptide, or Protein> identity with the known rat 5 - HT1A, rat 5 - HT1B, rat 5 - HT1D, and human 5 - HT1E receptors, respectively."}, {"PMID": 8384716, "id": 8, "text": "HeLa cells transfected with the MR77 gene exhibited inhibition of adenylate cyclase in response to serotonin.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [66, 75], "name": "adenylate", "tok_span": [11, 13], "new_tok_span": [13, 15]}, {"ent_type": "CHEMICAL", "char_span": [99, 108], "name": "serotonin", "tok_span": [17, 18], "new_tok_span": [19, 20]}, {"ent_type": "GENE", "char_span": [32, 36], "name": "MR77", "tok_span": [5, 7], "new_tok_span": [6, 8]}, {"ent_type": "GENE", "char_span": [66, 83], "name": "adenylate cyclase", "tok_span": [11, 14], "new_tok_span": [13, 16]}], "relation_list": [{"subject": "serotonin", "sbj_char_span": [99, 108], "object": "adenylate cyclase", "obj_char_span": [66, 83], "rel_type": "inhibitor", "sbj_tok_span": [17, 18], "obj_tok_span": [11, 14], "new_sbj_tok_span": [19, 20], "new_obj_tok_span": [13, 16]}], "umls_entity_list": [{"mention": "MR77", "char_span": [32, 36], "sem_type": "Gene or Genome", "tok_span": [5, 7], "new_tok_span": [6, 8]}], "new_text": "HeLa cells transfected with the <START=Gene or Genome> MR77 <END=Gene or Genome> gene exhibited inhibition of adenylate cyclase in response to serotonin."}, {"PMID": 16938288, "id": 6, "text": "RESULTS: Telmisartan decreased the expression of AT1R at the mRNA and protein levels in a dose- and time-dependent manner.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [9, 20], "name": "Telmisartan", "tok_span": [2, 7], "new_tok_span": [2, 7]}, {"ent_type": "GENE", "char_span": [49, 53], "name": "AT1R", "tok_span": [11, 14], "new_tok_span": [11, 14]}], "relation_list": [{"subject": "Telmisartan", "sbj_char_span": [9, 20], "object": "AT1R", "obj_char_span": [49, 53], "rel_type": "regulator", "sbj_tok_span": [2, 7], "obj_tok_span": [11, 14], "new_sbj_tok_span": [2, 7], "new_obj_tok_span": [11, 14]}], "umls_entity_list": [], "new_text": "RESULTS : Telmisartan decreased the expression of AT1R at the mRNA and protein levels in a dose - and time - dependent manner."}, {"PMID": 16938288, "id": 9, "text": "Since the suppression of AT1R expression was prevented by pretreatment with GW9662, a PPARgamma antagonist, PPARgamma should have participated in the process.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [76, 82], "name": "GW9662", "tok_span": [13, 16], "new_tok_span": [15, 18]}, {"ent_type": "GENE", "char_span": [25, 29], "name": "AT1R", "tok_span": [4, 7], "new_tok_span": [5, 8]}, {"ent_type": "GENE", "char_span": [86, 95], "name": "PPARgamma", "tok_span": [18, 20], "new_tok_span": [20, 22]}, {"ent_type": "GENE", "char_span": [108, 117], "name": "PPARgamma", "tok_span": [22, 24], "new_tok_span": [24, 26]}], "relation_list": [{"subject": "GW9662", "sbj_char_span": [76, 82], "object": "AT1R", "obj_char_span": [25, 29], "rel_type": "regulator", "sbj_tok_span": [13, 16], "obj_tok_span": [4, 7], "new_sbj_tok_span": [15, 18], "new_obj_tok_span": [5, 8]}, {"subject": "GW9662", "sbj_char_span": [76, 82], "object": "PPARgamma", "obj_char_span": [86, 95], "rel_type": "agonist or antagonist", "sbj_tok_span": [13, 16], "obj_tok_span": [18, 20], "new_sbj_tok_span": [15, 18], "new_obj_tok_span": [20, 22]}], "umls_entity_list": [{"mention": "AT1R", "char_span": [25, 29], "sem_type": "Gene or Genome", "tok_span": [4, 7], "new_tok_span": [5, 8]}], "new_text": "Since the suppression of <START=Gene or Genome> AT1R <END=Gene or Genome> expression was prevented by pretreatment with GW9662, a PPARgamma antagonist, PPARgamma should have participated in the process."}, {"PMID": 17459764, "id": 3, "text": "We demonstrate that only treatment of HaCaT with GLA and EPA or a PPARgamma ligand (roziglitazone), induced COX-2 expression (protein and mRNA). Moreover stimulation of COX-2 promoter activity was increased by those PUFAs or rosiglitazone.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [49, 52], "name": "GLA", "tok_span": [10, 12], "new_tok_span": [10, 12]}, {"ent_type": "CHEMICAL", "char_span": [57, 60], "name": "EPA", "tok_span": [13, 14], "new_tok_span": [13, 14]}, {"ent_type": "CHEMICAL", "char_span": [84, 97], "name": "roziglitazone", "tok_span": [20, 24], "new_tok_span": [20, 24]}, {"ent_type": "CHEMICAL", "char_span": [216, 221], "name": "PUFAs", "tok_span": [49, 51], "new_tok_span": [50, 52]}, {"ent_type": "CHEMICAL", "char_span": [225, 238], "name": "rosiglitazone", "tok_span": [52, 57], "new_tok_span": [54, 59]}, {"ent_type": "GENE", "char_span": [66, 75], "name": "PPARgamma", "tok_span": [16, 18], "new_tok_span": [16, 18]}, {"ent_type": "GENE", "char_span": [108, 113], "name": "COX-2", "tok_span": [27, 30], "new_tok_span": [27, 30]}, {"ent_type": "GENE", "char_span": [169, 183], "name": "COX-2 promoter", "tok_span": [40, 44], "new_tok_span": [40, 44]}], "relation_list": [{"subject": "roziglitazone", "sbj_char_span": [84, 97], "object": "PPARgamma", "obj_char_span": [66, 75], "rel_type": "regulator", "sbj_tok_span": [20, 24], "obj_tok_span": [16, 18], "new_sbj_tok_span": [20, 24], "new_obj_tok_span": [16, 18]}, {"subject": "GLA", "sbj_char_span": [49, 52], "object": "COX-2", "obj_char_span": [108, 113], "rel_type": "regulator", "sbj_tok_span": [10, 12], "obj_tok_span": [27, 30], "new_sbj_tok_span": [10, 12], "new_obj_tok_span": [27, 30]}, {"subject": "EPA", "sbj_char_span": [57, 60], "object": "COX-2", "obj_char_span": [108, 113], "rel_type": "regulator", "sbj_tok_span": [13, 14], "obj_tok_span": [27, 30], "new_sbj_tok_span": [13, 14], "new_obj_tok_span": [27, 30]}, {"subject": "roziglitazone", "sbj_char_span": [84, 97], "object": "COX-2", "obj_char_span": [108, 113], "rel_type": "regulator", "sbj_tok_span": [20, 24], "obj_tok_span": [27, 30], "new_sbj_tok_span": [20, 24], "new_obj_tok_span": [27, 30]}, {"subject": "PUFAs", "sbj_char_span": [216, 221], "object": "COX-2 promoter", "obj_char_span": [169, 183], "rel_type": "activator", "sbj_tok_span": [49, 51], "obj_tok_span": [40, 44], "new_sbj_tok_span": [50, 52], "new_obj_tok_span": [40, 44]}, {"subject": "rosiglitazone", "sbj_char_span": [225, 238], "object": "COX-2 promoter", "obj_char_span": [169, 183], "rel_type": "activator", "sbj_tok_span": [52, 57], "obj_tok_span": [40, 44], "new_sbj_tok_span": [54, 59], "new_obj_tok_span": [40, 44]}], "umls_entity_list": [{"mention": "PUFAs", "char_span": [216, 221], "sem_type": "Organic Chemical", "tok_span": [49, 51], "new_tok_span": [50, 52]}], "new_text": "We demonstrate that only treatment of HaCaT with GLA and EPA or a PPARgamma ligand ( roziglitazone ), induced COX - 2 expression ( protein and mRNA ). Moreover stimulation of COX - 2 promoter activity was increased by those <START=Organic Chemical> PUFAs <END=Organic Chemical> or rosiglitazone."}, {"PMID": 17090056, "id": 1, "text": "Kinetic isotope effects (KIEs) and computer modeling using density functional theory were used to approximate the transition state of human 5'-methylthioadenosine phosphorylase (MTAP). KIEs were measured on the arsenolysis of 5'-methylthioadenosine (MTA) catalyzed by MTAP and were corrected for the forward commitment to catalysis.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [140, 162], "name": "5'-methylthioadenosine", "tok_span": [25, 33], "new_tok_span": [25, 33]}, {"ent_type": "CHEMICAL", "char_span": [226, 248], "name": "5'-methylthioadenosine", "tok_span": [49, 57], "new_tok_span": [53, 61]}, {"ent_type": "CHEMICAL", "char_span": [250, 253], "name": "MTA", "tok_span": [58, 60], "new_tok_span": [62, 64]}, {"ent_type": "GENE", "char_span": [134, 176], "name": "human 5'-methylthioadenosine phosphorylase", "tok_span": [24, 35], "new_tok_span": [24, 35]}, {"ent_type": "GENE", "char_span": [178, 182], "name": "MTAP", "tok_span": [36, 38], "new_tok_span": [40, 42]}, {"ent_type": "GENE", "char_span": [268, 272], "name": "MTAP", "tok_span": [63, 65], "new_tok_span": [67, 69]}], "relation_list": [{"subject": "5'-methylthioadenosine", "sbj_char_span": [226, 248], "object": "MTAP", "obj_char_span": [268, 272], "rel_type": "product or substrate", "sbj_tok_span": [49, 57], "obj_tok_span": [63, 65], "new_sbj_tok_span": [53, 61], "new_obj_tok_span": [67, 69]}, {"subject": "MTA", "sbj_char_span": [250, 253], "object": "MTAP", "obj_char_span": [268, 272], "rel_type": "product or substrate", "sbj_tok_span": [58, 60], "obj_tok_span": [63, 65], "new_sbj_tok_span": [62, 64], "new_obj_tok_span": [67, 69]}], "umls_entity_list": [{"mention": "methylthioadenosine phosphorylase", "char_span": [143, 176], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [28, 35], "new_tok_span": [30, 37]}, {"mention": "methylthioadenosine phosphorylase", "char_span": [143, 176], "sem_type": "Gene or Genome", "tok_span": [28, 35], "new_tok_span": [30, 37]}], "new_text": "Kinetic isotope effects ( KIEs ) and computer modeling using density functional theory were used to approximate the transition state of human 5'- <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> methylthioadenosine phosphorylase <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> ( MTAP ). KIEs were measured on the arsenolysis of 5'- methylthioadenosine ( MTA ) catalyzed by MTAP and were corrected for the forward commitment to catalysis."}, {"PMID": 2982865, "id": 4, "text": "However, in the presence of 100 mM Na+, which is required for opiate inhibition of adenylate cyclase activity, analysis of competition binding data revealed three sites: the first, consisting of 17.5% of total receptor population has a Kd = 0.38 +/- 0.18 nM; the second, 50.6% of the population, has a Kd = 6.8 +/- 2.2 nM; and the third, 31.9% of the population, has a Kd of 410 +/- 110 nM.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [35, 38], "name": "Na+", "tok_span": [8, 10], "new_tok_span": [8, 10]}, {"ent_type": "CHEMICAL", "char_span": [83, 92], "name": "adenylate", "tok_span": [19, 21], "new_tok_span": [21, 23]}, {"ent_type": "GENE", "char_span": [83, 100], "name": "adenylate cyclase", "tok_span": [19, 22], "new_tok_span": [21, 24]}], "relation_list": [{"subject": "Na+", "sbj_char_span": [35, 38], "object": "adenylate cyclase", "obj_char_span": [83, 100], "rel_type": "inhibitor", "sbj_tok_span": [8, 10], "obj_tok_span": [19, 22], "new_sbj_tok_span": [8, 10], "new_obj_tok_span": [21, 24]}], "umls_entity_list": [{"mention": "opiate", "char_span": [62, 68], "sem_type": "Pharmacologic Substance", "tok_span": [15, 17], "new_tok_span": [16, 18]}], "new_text": "However, in the presence of 100 mM Na +, which is required for <START=Pharmacologic Substance> opiate <END=Pharmacologic Substance> inhibition of adenylate cyclase activity, analysis of competition binding data revealed three sites : the first, consisting of 17. 5 % of total receptor population has a Kd = 0. 38 + / - 0. 18 nM ; the second, 50. 6 % of the population, has a Kd = 6. 8 + / - 2. 2 nM ; and the third, 31. 9 % of the population, has a Kd of 410 + / - 110 nM."}, {"PMID": 3345199, "id": 0, "text": "Effects of some mono- and bisquaternary ammonium compounds on the reactivatability of soman-inhibited human acetylcholinesterase in vitro.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [16, 48], "name": "mono- and bisquaternary ammonium", "tok_span": [3, 11], "new_tok_span": [3, 11]}, {"ent_type": "CHEMICAL", "char_span": [86, 91], "name": "soman", "tok_span": [19, 21], "new_tok_span": [22, 24]}, {"ent_type": "GENE", "char_span": [102, 128], "name": "human acetylcholinesterase", "tok_span": [23, 27], "new_tok_span": [27, 31]}], "relation_list": [{"subject": "soman", "sbj_char_span": [86, 91], "object": "human acetylcholinesterase", "obj_char_span": [102, 128], "rel_type": "inhibitor", "sbj_tok_span": [19, 21], "obj_tok_span": [23, 27], "new_sbj_tok_span": [22, 24], "new_obj_tok_span": [27, 31]}], "umls_entity_list": [{"mention": "bisquaternary ammonium compounds", "char_span": [26, 58], "sem_type": "Pharmacologic Substance", "tok_span": [6, 12], "new_tok_span": [7, 13]}, {"mention": "soman", "char_span": [86, 91], "sem_type": "Organic Chemical", "tok_span": [19, 21], "new_tok_span": [22, 24]}], "new_text": "Effects of some mono - and <START=Pharmacologic Substance> bisquaternary ammonium compounds <END=Pharmacologic Substance> on the reactivatability of <START=Organic Chemical> soman <END=Organic Chemical> - inhibited human acetylcholinesterase in vitro."}, {"PMID": 23543413, "id": 5, "text": "We compared the uptake rates of copper with cDDP (and several analogs) into HEK293 cells over-expressing wild-type or mutant hCTR1, mouse embryonic fibroblasts (mefs) that do or do not express CTR1, and human ovarian tumor cells, sensitive or resistant to cDDP. We have also compared the effects of extracellular copper, which causes regulatory endocytosis of hCTR1, to those of cDDP. We confirm the correlation between higher hCTR1 levels and higher Pt-drug uptake in tumor cells sensitive to the drug.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [256, 260], "name": "cDDP", "tok_span": [60, 63], "new_tok_span": [73, 76]}, {"ent_type": "CHEMICAL", "char_span": [313, 319], "name": "copper", "tok_span": [72, 73], "new_tok_span": [87, 88]}, {"ent_type": "CHEMICAL", "char_span": [379, 383], "name": "cDDP", "tok_span": [87, 90], "new_tok_span": [110, 113]}, {"ent_type": "CHEMICAL", "char_span": [451, 453], "name": "Pt", "tok_span": [104, 105], "new_tok_span": [134, 135]}, {"ent_type": "GENE", "char_span": [125, 130], "name": "hCTR1", "tok_span": [28, 32], "new_tok_span": [34, 38]}, {"ent_type": "GENE", "char_span": [193, 197], "name": "CTR1", "tok_span": [46, 49], "new_tok_span": [57, 60]}, {"ent_type": "GENE", "char_span": [360, 365], "name": "hCTR1", "tok_span": [79, 83], "new_tok_span": [97, 101]}, {"ent_type": "GENE", "char_span": [427, 432], "name": "hCTR1", "tok_span": [97, 101], "new_tok_span": [123, 127]}], "relation_list": [{"subject": "Pt", "sbj_char_span": [451, 453], "object": "hCTR1", "obj_char_span": [427, 432], "rel_type": "product or substrate", "sbj_tok_span": [104, 105], "obj_tok_span": [97, 101], "new_sbj_tok_span": [134, 135], "new_obj_tok_span": [123, 127]}], "umls_entity_list": [{"mention": "copper", "char_span": [32, 38], "sem_type": "Pharmacologic Substance", "tok_span": [6, 7], "new_tok_span": [7, 8]}, {"mention": "copper", "char_span": [313, 319], "sem_type": "Pharmacologic Substance", "tok_span": [72, 73], "new_tok_span": [87, 88]}, {"mention": "hCTR1", "char_span": [125, 130], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [28, 32], "new_tok_span": [34, 38]}, {"mention": "hCTR1", "char_span": [360, 365], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [79, 83], "new_tok_span": [97, 101]}, {"mention": "hCTR1", "char_span": [427, 432], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [97, 101], "new_tok_span": [123, 127]}, {"mention": "hCTR1", "char_span": [125, 130], "sem_type": "Gene or Genome", "tok_span": [28, 32], "new_tok_span": [34, 38]}, {"mention": "hCTR1", "char_span": [360, 365], "sem_type": "Gene or Genome", "tok_span": [79, 83], "new_tok_span": [97, 101]}, {"mention": "hCTR1", "char_span": [427, 432], "sem_type": "Gene or Genome", "tok_span": [97, 101], "new_tok_span": [123, 127]}, {"mention": "CTR1", "char_span": [126, 130], "sem_type": "Gene or Genome", "tok_span": [29, 32], "new_tok_span": [36, 39]}, {"mention": "CTR1", "char_span": [193, 197], "sem_type": "Gene or Genome", "tok_span": [46, 49], "new_tok_span": [57, 60]}, {"mention": "CTR1", "char_span": [361, 365], "sem_type": "Gene or Genome", "tok_span": [80, 83], "new_tok_span": [99, 102]}, {"mention": "CTR1", "char_span": [428, 432], "sem_type": "Gene or Genome", "tok_span": [98, 101], "new_tok_span": [125, 128]}, {"mention": "cDDP", "char_span": [44, 48], "sem_type": "Pharmacologic Substance", "tok_span": [8, 11], "new_tok_span": [11, 14]}, {"mention": "cDDP", "char_span": [256, 260], "sem_type": "Pharmacologic Substance", "tok_span": [60, 63], "new_tok_span": [73, 76]}, {"mention": "cDDP", "char_span": [379, 383], "sem_type": "Pharmacologic Substance", "tok_span": [87, 90], "new_tok_span": [110, 113]}], "new_text": "We compared the uptake rates of <START=Pharmacologic Substance> copper <END=Pharmacologic Substance> with <START=Pharmacologic Substance> cDDP <END=Pharmacologic Substance> ( and several analogs ) into HEK293 cells over - expressing wild - type or mutant <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> h <START=Gene or Genome>CTR1 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> <END=Gene or Genome>, mouse embryonic fibroblasts ( mefs ) that do or don't express <START=Gene or Genome> CTR1 <END=Gene or Genome>, and human ovarian tumor cells, sensitive or resistant to <START=Pharmacologic Substance> cDDP <END=Pharmacologic Substance>. We have also compared the effects of extracellular <START=Pharmacologic Substance> copper <END=Pharmacologic Substance>, which causes regulatory endocytosis of <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> h <START=Gene or Genome>CTR1 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> <END=Gene or Genome>, to those of <START=Pharmacologic Substance> cDDP <END=Pharmacologic Substance>. We confirm the correlation between higher <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> h <START=Gene or Genome>CTR1 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> <END=Gene or Genome> levels and higher Pt - drug uptake in tumor cells sensitive to the drug."}, {"PMID": 20104269, "id": 5, "text": "CDCA induced dose-dependent expression of Cdx2 and MUC2 at both the mRNA and protein levels.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 4], "name": "CDCA", "tok_span": [0, 2], "new_tok_span": [0, 2]}, {"ent_type": "GENE", "char_span": [42, 46], "name": "Cdx2", "tok_span": [8, 11], "new_tok_span": [8, 11]}, {"ent_type": "GENE", "char_span": [51, 55], "name": "MUC2", "tok_span": [12, 15], "new_tok_span": [14, 17]}], "relation_list": [{"subject": "CDCA", "sbj_char_span": [0, 4], "object": "Cdx2", "obj_char_span": [42, 46], "rel_type": "regulator", "sbj_tok_span": [0, 2], "obj_tok_span": [8, 11], "new_sbj_tok_span": [0, 2], "new_obj_tok_span": [8, 11]}, {"subject": "CDCA", "sbj_char_span": [0, 4], "object": "MUC2", "obj_char_span": [51, 55], "rel_type": "regulator", "sbj_tok_span": [0, 2], "obj_tok_span": [12, 15], "new_sbj_tok_span": [0, 2], "new_obj_tok_span": [14, 17]}], "umls_entity_list": [{"mention": "MUC2", "char_span": [51, 55], "sem_type": "Gene or Genome", "tok_span": [12, 15], "new_tok_span": [14, 17]}, {"mention": "MUC2", "char_span": [51, 55], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [12, 15], "new_tok_span": [14, 17]}], "new_text": "CDCA induced dose - dependent expression of Cdx2 and <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> MUC2 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> at both the mRNA and protein levels."}, {"PMID": 9551716, "id": 3, "text": "Saturation and competition studies in the presence or absence of the histamine H1 receptor antagonist, levocabastine, revealed that [3H]SR 142948A bound with similar affinities to both the levocabastine-insensitive neurotensin NT1 receptors (20% of the total binding population) and the recently cloned levocabastine-sensitive neurotensin NT2 receptors (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively).", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [69, 78], "name": "histamine", "tok_span": [12, 13], "new_tok_span": [13, 14]}, {"ent_type": "CHEMICAL", "char_span": [103, 116], "name": "levocabastine", "tok_span": [18, 23], "new_tok_span": [21, 26]}, {"ent_type": "CHEMICAL", "char_span": [132, 146], "name": "[3H]SR 142948A", "tok_span": [26, 35], "new_tok_span": [30, 39]}, {"ent_type": "CHEMICAL", "char_span": [189, 202], "name": "levocabastine", "tok_span": [42, 47], "new_tok_span": [47, 52]}, {"ent_type": "CHEMICAL", "char_span": [215, 226], "name": "neurotensin", "tok_span": [49, 51], "new_tok_span": [55, 57]}, {"ent_type": "CHEMICAL", "char_span": [303, 316], "name": "levocabastine", "tok_span": [67, 72], "new_tok_span": [76, 81]}, {"ent_type": "GENE", "char_span": [69, 90], "name": "histamine H1 receptor", "tok_span": [12, 16], "new_tok_span": [13, 17]}, {"ent_type": "GENE", "char_span": [215, 240], "name": "neurotensin NT1 receptors", "tok_span": [49, 54], "new_tok_span": [55, 60]}, {"ent_type": "GENE", "char_span": [327, 352], "name": "neurotensin NT2 receptors", "tok_span": [74, 79], "new_tok_span": [84, 89]}], "relation_list": [{"subject": "[3H]SR 142948A", "sbj_char_span": [132, 146], "object": "neurotensin NT1 receptors", "obj_char_span": [215, 240], "rel_type": "regulator", "sbj_tok_span": [26, 35], "obj_tok_span": [49, 54], "new_sbj_tok_span": [30, 39], "new_obj_tok_span": [55, 60]}, {"subject": "[3H]SR 142948A", "sbj_char_span": [132, 146], "object": "neurotensin NT2 receptors", "obj_char_span": [327, 352], "rel_type": "regulator", "sbj_tok_span": [26, 35], "obj_tok_span": [74, 79], "new_sbj_tok_span": [30, 39], "new_obj_tok_span": [84, 89]}, {"subject": "levocabastine", "sbj_char_span": [103, 116], "object": "histamine H1 receptor", "obj_char_span": [69, 90], "rel_type": "agonist or antagonist", "sbj_tok_span": [18, 23], "obj_tok_span": [12, 16], "new_sbj_tok_span": [21, 26], "new_obj_tok_span": [13, 17]}], "umls_entity_list": [{"mention": "histamine H1 receptor antagonist", "char_span": [69, 101], "sem_type": "Pharmacologic Substance", "tok_span": [12, 17], "new_tok_span": [13, 18]}, {"mention": "levocabastine", "char_span": [103, 116], "sem_type": "Pharmacologic Substance", "tok_span": [18, 23], "new_tok_span": [21, 26]}, {"mention": "levocabastine", "char_span": [189, 202], "sem_type": "Pharmacologic Substance", "tok_span": [42, 47], "new_tok_span": [47, 52]}, {"mention": "levocabastine", "char_span": [303, 316], "sem_type": "Pharmacologic Substance", "tok_span": [67, 72], "new_tok_span": [76, 81]}, {"mention": "eceptors", "char_span": [232, 240], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [53, 54], "new_tok_span": [60, 61]}, {"mention": "eceptors", "char_span": [344, 352], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [78, 79], "new_tok_span": [89, 90]}, {"mention": "eceptors", "char_span": [366, 374], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [84, 85], "new_tok_span": [97, 98]}], "new_text": "Saturation and competition studies in the presence or absence of the <START=Pharmacologic Substance> histamine H1 receptor antagonist <END=Pharmacologic Substance>, <START=Pharmacologic Substance> levocabastine <END=Pharmacologic Substance>, revealed that [ 3H ] SR 142948A bound with similar affinities to both the <START=Pharmacologic Substance> levocabastine <END=Pharmacologic Substance> - insensitive neurotensin NT1 <START=Amino Acid, Peptide, or Protein> receptors <END=Amino Acid, Peptide, or Protein> ( 20 % of the total binding population ) and the recently cloned <START=Pharmacologic Substance> levocabastine <END=Pharmacologic Substance> - sensitive neurotensin NT2 <START=Amino Acid, Peptide, or Protein> receptors <END=Amino Acid, Peptide, or Protein> ( 80 % of the <START=Amino Acid, Peptide, or Protein> receptors <END=Amino Acid, Peptide, or Protein> ) ( Kd = 6. 8 and 4. 8 nM, respectively )."}, {"PMID": 23159529, "id": 0, "text": "Nanobody-albumin nanoparticles (NANAPs) for the delivery of a multikinase inhibitor 17864 to EGFR overexpressing tumor cells.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [84, 89], "name": "17864", "tok_span": [18, 20], "new_tok_span": [18, 20]}, {"ent_type": "GENE", "char_span": [62, 73], "name": "multikinase", "tok_span": [15, 17], "new_tok_span": [15, 17]}, {"ent_type": "GENE", "char_span": [9, 16], "name": "albumin", "tok_span": [3, 4], "new_tok_span": [3, 4]}, {"ent_type": "GENE", "char_span": [93, 97], "name": "EGFR", "tok_span": [21, 22], "new_tok_span": [21, 22]}], "relation_list": [{"subject": "17864", "sbj_char_span": [84, 89], "object": "multikinase", "obj_char_span": [62, 73], "rel_type": "inhibitor", "sbj_tok_span": [18, 20], "obj_tok_span": [15, 17], "new_sbj_tok_span": [18, 20], "new_obj_tok_span": [15, 17]}], "umls_entity_list": [], "new_text": "Nanobody - albumin nanoparticles ( NANAPs ) for the delivery of a multikinase inhibitor 17864 to EGFR overexpressing tumor cells."}, {"PMID": 14523001, "id": 2, "text": "Cat-1, the transporter for the essential amino acids, arginine and lysine, is one of the up-regulated genes.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [41, 52], "name": "amino acids", "tok_span": [9, 11], "new_tok_span": [13, 15]}, {"ent_type": "CHEMICAL", "char_span": [54, 62], "name": "arginine", "tok_span": [12, 13], "new_tok_span": [16, 17]}, {"ent_type": "CHEMICAL", "char_span": [67, 73], "name": "lysine", "tok_span": [14, 15], "new_tok_span": [18, 19]}, {"ent_type": "GENE", "char_span": [0, 5], "name": "Cat-1", "tok_span": [0, 3], "new_tok_span": [1, 4]}], "relation_list": [{"subject": "amino acids", "sbj_char_span": [41, 52], "object": "Cat-1", "obj_char_span": [0, 5], "rel_type": "product or substrate", "sbj_tok_span": [9, 11], "obj_tok_span": [0, 3], "new_sbj_tok_span": [13, 15], "new_obj_tok_span": [1, 4]}, {"subject": "arginine", "sbj_char_span": [54, 62], "object": "Cat-1", "obj_char_span": [0, 5], "rel_type": "product or substrate", "sbj_tok_span": [12, 13], "obj_tok_span": [0, 3], "new_sbj_tok_span": [16, 17], "new_obj_tok_span": [1, 4]}, {"subject": "lysine", "sbj_char_span": [67, 73], "object": "Cat-1", "obj_char_span": [0, 5], "rel_type": "product or substrate", "sbj_tok_span": [14, 15], "obj_tok_span": [0, 3], "new_sbj_tok_span": [18, 19], "new_obj_tok_span": [1, 4]}], "umls_entity_list": [{"mention": "Cat-1", "char_span": [0, 5], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [0, 3], "new_tok_span": [1, 4]}, {"mention": "transporter", "char_span": [11, 22], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [5, 6], "new_tok_span": [8, 9]}], "new_text": "<START=Amino Acid, Peptide, or Protein> Cat - 1 <END=Amino Acid, Peptide, or Protein>, the <START=Amino Acid, Peptide, or Protein> transporter <END=Amino Acid, Peptide, or Protein> for the essential amino acids, arginine and lysine, is one of the up - regulated genes."}, {"PMID": 15805193, "id": 5, "text": "Phenytoin is principally metabolized by CYP2C9, and both are probable substrates of the drug transporter P-glycoprotein.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 9], "name": "Phenytoin", "tok_span": [0, 3], "new_tok_span": [0, 3]}, {"ent_type": "GENE", "char_span": [40, 46], "name": "CYP2C9", "tok_span": [9, 13], "new_tok_span": [9, 13]}, {"ent_type": "GENE", "char_span": [88, 104], "name": "drug transporter", "tok_span": [21, 23], "new_tok_span": [21, 23]}, {"ent_type": "GENE", "char_span": [105, 119], "name": "P-glycoprotein", "tok_span": [23, 26], "new_tok_span": [23, 26]}], "relation_list": [{"subject": "Phenytoin", "sbj_char_span": [0, 9], "object": "CYP2C9", "obj_char_span": [40, 46], "rel_type": "product or substrate", "sbj_tok_span": [0, 3], "obj_tok_span": [9, 13], "new_sbj_tok_span": [0, 3], "new_obj_tok_span": [9, 13]}, {"subject": "Phenytoin", "sbj_char_span": [0, 9], "object": "drug transporter", "obj_char_span": [88, 104], "rel_type": "product or substrate", "sbj_tok_span": [0, 3], "obj_tok_span": [21, 23], "new_sbj_tok_span": [0, 3], "new_obj_tok_span": [21, 23]}, {"subject": "Phenytoin", "sbj_char_span": [0, 9], "object": "P-glycoprotein", "obj_char_span": [105, 119], "rel_type": "product or substrate", "sbj_tok_span": [0, 3], "obj_tok_span": [23, 26], "new_sbj_tok_span": [0, 3], "new_obj_tok_span": [23, 26]}], "umls_entity_list": [], "new_text": "Phenytoin is principally metabolized by CYP2C9, and both are probable substrates of the drug transporter P - glycoprotein."}, {"PMID": 20185318, "id": 1, "text": "Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [72, 83], "name": "polyphenols", "tok_span": [14, 16], "new_tok_span": [15, 17]}, {"ent_type": "CHEMICAL", "char_span": [88, 102], "name": "phenolic acids", "tok_span": [17, 19], "new_tok_span": [20, 22]}, {"ent_type": "GENE", "char_span": [14, 38], "name": "mammalian isoforms I-XIV", "tok_span": [2, 8], "new_tok_span": [2, 8]}], "relation_list": [{"subject": "polyphenols", "sbj_char_span": [72, 83], "object": "mammalian isoforms I-XIV", "obj_char_span": [14, 38], "rel_type": "inhibitor", "sbj_tok_span": [14, 16], "obj_tok_span": [2, 8], "new_sbj_tok_span": [15, 17], "new_obj_tok_span": [2, 8]}, {"subject": "phenolic acids", "sbj_char_span": [88, 102], "object": "mammalian isoforms I-XIV", "obj_char_span": [14, 38], "rel_type": "inhibitor", "sbj_tok_span": [17, 19], "obj_tok_span": [2, 8], "new_sbj_tok_span": [20, 22], "new_obj_tok_span": [2, 8]}], "umls_entity_list": [{"mention": "polyphenols", "char_span": [72, 83], "sem_type": "Pharmacologic Substance", "tok_span": [14, 16], "new_tok_span": [15, 17]}, {"mention": "phenolic acid", "char_span": [88, 101], "sem_type": "Organic Chemical", "tok_span": [17, 19], "new_tok_span": [20, 22]}], "new_text": "Inhibition of mammalian isoforms I - XIV with a series of natural product <START=Pharmacologic Substance> polyphenols <END=Pharmacologic Substance> and <START=Organic Chemical> phenolic acids <END=Organic Chemical>."}, {"PMID": 23261590, "id": 8, "text": "The molecular mechanism studies suggested that neoechinulin A may block the phosphorylation of mitogen-activated protein kinase (MAPK) molecule p38, apoptosis signal-regulating kinase 1 (ASK-1) and nuclear translocation of nuclear factor-κB (NF-κB) p65 and p50 subunits.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [47, 61], "name": "neoechinulin A", "tok_span": [6, 11], "new_tok_span": [6, 11]}, {"ent_type": "GENE", "char_span": [95, 127], "name": "mitogen-activated protein kinase", "tok_span": [16, 21], "new_tok_span": [16, 21]}, {"ent_type": "GENE", "char_span": [129, 133], "name": "MAPK", "tok_span": [22, 23], "new_tok_span": [22, 23]}, {"ent_type": "GENE", "char_span": [144, 147], "name": "p38", "tok_span": [25, 27], "new_tok_span": [25, 27]}, {"ent_type": "GENE", "char_span": [149, 185], "name": "apoptosis signal-regulating kinase 1", "tok_span": [28, 34], "new_tok_span": [30, 36]}, {"ent_type": "GENE", "char_span": [187, 192], "name": "ASK-1", "tok_span": [35, 39], "new_tok_span": [40, 44]}, {"ent_type": "GENE", "char_span": [223, 240], "name": "nuclear factor-κB", "tok_span": [44, 49], "new_tok_span": [50, 55]}, {"ent_type": "GENE", "char_span": [242, 247], "name": "NF-κB", "tok_span": [50, 54], "new_tok_span": [56, 60]}, {"ent_type": "GENE", "char_span": [249, 252], "name": "p65", "tok_span": [55, 57], "new_tok_span": [61, 63]}, {"ent_type": "GENE", "char_span": [257, 260], "name": "p50", "tok_span": [58, 60], "new_tok_span": [65, 67]}], "relation_list": [{"subject": "neoechinulin A", "sbj_char_span": [47, 61], "object": "mitogen-activated protein kinase", "obj_char_span": [95, 127], "rel_type": "inhibitor", "sbj_tok_span": [6, 11], "obj_tok_span": [16, 21], "new_sbj_tok_span": [6, 11], "new_obj_tok_span": [16, 21]}, {"subject": "neoechinulin A", "sbj_char_span": [47, 61], "object": "MAPK", "obj_char_span": [129, 133], "rel_type": "inhibitor", "sbj_tok_span": [6, 11], "obj_tok_span": [22, 23], "new_sbj_tok_span": [6, 11], "new_obj_tok_span": [22, 23]}, {"subject": "neoechinulin A", "sbj_char_span": [47, 61], "object": "p38", "obj_char_span": [144, 147], "rel_type": "inhibitor", "sbj_tok_span": [6, 11], "obj_tok_span": [25, 27], "new_sbj_tok_span": [6, 11], "new_obj_tok_span": [25, 27]}, {"subject": "neoechinulin A", "sbj_char_span": [47, 61], "object": "apoptosis signal-regulating kinase 1", "obj_char_span": [149, 185], "rel_type": "inhibitor", "sbj_tok_span": [6, 11], "obj_tok_span": [28, 34], "new_sbj_tok_span": [6, 11], "new_obj_tok_span": [30, 36]}, {"subject": "neoechinulin A", "sbj_char_span": [47, 61], "object": "ASK-1", "obj_char_span": [187, 192], "rel_type": "inhibitor", "sbj_tok_span": [6, 11], "obj_tok_span": [35, 39], "new_sbj_tok_span": [6, 11], "new_obj_tok_span": [40, 44]}, {"subject": "neoechinulin A", "sbj_char_span": [47, 61], "object": "nuclear factor-κB", "obj_char_span": [223, 240], "rel_type": "regulator", "sbj_tok_span": [6, 11], "obj_tok_span": [44, 49], "new_sbj_tok_span": [6, 11], "new_obj_tok_span": [50, 55]}, {"subject": "neoechinulin A", "sbj_char_span": [47, 61], "object": "NF-κB", "obj_char_span": [242, 247], "rel_type": "regulator", "sbj_tok_span": [6, 11], "obj_tok_span": [50, 54], "new_sbj_tok_span": [6, 11], "new_obj_tok_span": [56, 60]}, {"subject": "neoechinulin A", "sbj_char_span": [47, 61], "object": "p65", "obj_char_span": [249, 252], "rel_type": "regulator", "sbj_tok_span": [6, 11], "obj_tok_span": [55, 57], "new_sbj_tok_span": [6, 11], "new_obj_tok_span": [61, 63]}, {"subject": "neoechinulin A", "sbj_char_span": [47, 61], "object": "p50", "obj_char_span": [257, 260], "rel_type": "regulator", "sbj_tok_span": [6, 11], "obj_tok_span": [58, 60], "new_sbj_tok_span": [6, 11], "new_obj_tok_span": [65, 67]}], "umls_entity_list": [{"mention": "apoptosis signal-regulating kinase 1", "char_span": [149, 185], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [28, 34], "new_tok_span": [30, 36]}, {"mention": "apoptosis signal-regulating kinase 1", "char_span": [149, 185], "sem_type": "Gene or Genome", "tok_span": [28, 34], "new_tok_span": [30, 36]}, {"mention": "ASK-1", "char_span": [187, 192], "sem_type": "Gene or Genome", "tok_span": [35, 39], "new_tok_span": [40, 44]}, {"mention": "p50", "char_span": [257, 260], "sem_type": "Gene or Genome", "tok_span": [58, 60], "new_tok_span": [65, 67]}], "new_text": "The molecular mechanism studies suggested that neoechinulin A may block the phosphorylation of mitogen - activated protein kinase ( MAPK ) molecule p38, <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> apoptosis signal - regulating kinase 1 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> ( <START=Gene or Genome> ASK - 1 <END=Gene or Genome> ) and nuclear translocation of nuclear factor - κB ( NF - κB ) p65 and <START=Gene or Genome> p50 <END=Gene or Genome> subunits."}, {"PMID": 23435910, "id": 9, "text": "In conclusion, we find that sinapic acid exhibits hepatoprotective and antifibrotic effects against DMN-induced liver injury, most likely due to its antioxidant activities of scavenging radicals, its capacity to suppress TGF-β1 and its ability to attenuate activation of hepatic stellate cells.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [28, 40], "name": "sinapic acid", "tok_span": [6, 10], "new_tok_span": [6, 10]}, {"ent_type": "CHEMICAL", "char_span": [100, 103], "name": "DMN", "tok_span": [19, 21], "new_tok_span": [19, 21]}, {"ent_type": "GENE", "char_span": [221, 227], "name": "TGF-β1", "tok_span": [41, 45], "new_tok_span": [43, 47]}], "relation_list": [{"subject": "sinapic acid", "sbj_char_span": [28, 40], "object": "TGF-β1", "obj_char_span": [221, 227], "rel_type": "regulator", "sbj_tok_span": [6, 10], "obj_tok_span": [41, 45], "new_sbj_tok_span": [6, 10], "new_obj_tok_span": [43, 47]}], "umls_entity_list": [{"mention": "antioxidant", "char_span": [149, 160], "sem_type": "Pharmacologic Substance", "tok_span": [31, 32], "new_tok_span": [32, 33]}], "new_text": "In conclusion, we find that sinapic acid exhibits hepatoprotective and antifibrotic effects against DMN - induced liver injury, most likely due to its <START=Pharmacologic Substance> antioxidant <END=Pharmacologic Substance> activities of scavenging radicals, its capacity to suppress TGF - β1 and its ability to attenuate activation of hepatic stellate cells."}, {"PMID": 22902329, "id": 2, "text": "We previously demonstrated that the somatostatinergic system, implicated in neuronal survival control, can be modulated by α-tocopherol in the rat dentate gyrus, increasing cyclic adenosine monophosphate response element binding protein phosphorylation.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [123, 135], "name": "α-tocopherol", "tok_span": [20, 26], "new_tok_span": [20, 26]}, {"ent_type": "CHEMICAL", "char_span": [173, 203], "name": "cyclic adenosine monophosphate", "tok_span": [34, 41], "new_tok_span": [34, 41]}, {"ent_type": "GENE", "char_span": [173, 236], "name": "cyclic adenosine monophosphate response element binding protein", "tok_span": [34, 45], "new_tok_span": [34, 45]}], "relation_list": [{"subject": "α-tocopherol", "sbj_char_span": [123, 135], "object": "cyclic adenosine monophosphate response element binding protein", "obj_char_span": [173, 236], "rel_type": "activator", "sbj_tok_span": [20, 26], "obj_tok_span": [34, 45], "new_sbj_tok_span": [20, 26], "new_obj_tok_span": [34, 45]}], "umls_entity_list": [], "new_text": "We previously demonstrated that the somatostatinergic system, implicated in neuronal survival control, can be modulated by α - tocopherol in the rat dentate gyrus, increasing cyclic adenosine monophosphate response element binding protein phosphorylation."}, {"PMID": 14600253, "id": 4, "text": "Glycylsarcosine coadministration could inhibit the uptake of cefadroxil in PEPT2(+/+) mice (p < 0.01) but not PEPT2(-/-) mice.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 15], "name": "Glycylsarcosine", "tok_span": [0, 5], "new_tok_span": [1, 6]}, {"ent_type": "CHEMICAL", "char_span": [61, 71], "name": "cefadroxil", "tok_span": [12, 16], "new_tok_span": [14, 18]}, {"ent_type": "GENE", "char_span": [75, 80], "name": "PEPT2", "tok_span": [17, 20], "new_tok_span": [19, 22]}, {"ent_type": "GENE", "char_span": [110, 115], "name": "PEPT2", "tok_span": [35, 38], "new_tok_span": [37, 40]}], "relation_list": [{"subject": "Glycylsarcosine", "sbj_char_span": [0, 15], "object": "PEPT2", "obj_char_span": [75, 80], "rel_type": "regulator", "sbj_tok_span": [0, 5], "obj_tok_span": [17, 20], "new_sbj_tok_span": [1, 6], "new_obj_tok_span": [19, 22]}, {"subject": "cefadroxil", "sbj_char_span": [61, 71], "object": "PEPT2", "obj_char_span": [75, 80], "rel_type": "product or substrate", "sbj_tok_span": [12, 16], "obj_tok_span": [17, 20], "new_sbj_tok_span": [14, 18], "new_obj_tok_span": [19, 22]}, {"subject": "cefadroxil", "sbj_char_span": [61, 71], "object": "PEPT2", "obj_char_span": [110, 115], "rel_type": "product or substrate", "sbj_tok_span": [12, 16], "obj_tok_span": [35, 38], "new_sbj_tok_span": [14, 18], "new_obj_tok_span": [37, 40]}], "umls_entity_list": [{"mention": "Glycylsarcosine", "char_span": [0, 15], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [0, 5], "new_tok_span": [1, 6]}], "new_text": "<START=Amino Acid, Peptide, or Protein> Glycylsarcosine <END=Amino Acid, Peptide, or Protein> coadministration could inhibit the uptake of cefadroxil in PEPT2 ( + / + ) mice ( p < 0. 01 ) but not PEPT2 ( - / - ) mice."}, {"PMID": 23625804, "id": 2, "text": "We recently showed that the first domain of human CCS (hCCSD1) is responsible for copper transfer to its protein partner, human SOD1 (hSOD1).", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [82, 88], "name": "copper", "tok_span": [19, 20], "new_tok_span": [20, 21]}, {"ent_type": "GENE", "char_span": [44, 53], "name": "human CCS", "tok_span": [8, 10], "new_tok_span": [8, 10]}, {"ent_type": "GENE", "char_span": [55, 61], "name": "hCCSD1", "tok_span": [11, 15], "new_tok_span": [11, 15]}, {"ent_type": "GENE", "char_span": [122, 132], "name": "human SOD1", "tok_span": [26, 29], "new_tok_span": [28, 31]}, {"ent_type": "GENE", "char_span": [134, 139], "name": "hSOD1", "tok_span": [30, 33], "new_tok_span": [37, 40]}], "relation_list": [{"subject": "copper", "sbj_char_span": [82, 88], "object": "human CCS", "obj_char_span": [44, 53], "rel_type": "regulator", "sbj_tok_span": [19, 20], "obj_tok_span": [8, 10], "new_sbj_tok_span": [20, 21], "new_obj_tok_span": [8, 10]}, {"subject": "copper", "sbj_char_span": [82, 88], "object": "hCCSD1", "obj_char_span": [55, 61], "rel_type": "regulator", "sbj_tok_span": [19, 20], "obj_tok_span": [11, 15], "new_sbj_tok_span": [20, 21], "new_obj_tok_span": [11, 15]}, {"subject": "copper", "sbj_char_span": [82, 88], "object": "human SOD1", "obj_char_span": [122, 132], "rel_type": "regulator", "sbj_tok_span": [19, 20], "obj_tok_span": [26, 29], "new_sbj_tok_span": [20, 21], "new_obj_tok_span": [28, 31]}, {"subject": "copper", "sbj_char_span": [82, 88], "object": "hSOD1", "obj_char_span": [134, 139], "rel_type": "regulator", "sbj_tok_span": [19, 20], "obj_tok_span": [30, 33], "new_sbj_tok_span": [20, 21], "new_obj_tok_span": [37, 40]}], "umls_entity_list": [{"mention": "copper", "char_span": [82, 88], "sem_type": "Pharmacologic Substance", "tok_span": [19, 20], "new_tok_span": [20, 21]}, {"mention": "SOD1", "char_span": [128, 132], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [27, 29], "new_tok_span": [31, 33]}, {"mention": "SOD1", "char_span": [135, 139], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [31, 33], "new_tok_span": [40, 42]}, {"mention": "SOD1", "char_span": [128, 132], "sem_type": "Gene or Genome", "tok_span": [27, 29], "new_tok_span": [31, 33]}, {"mention": "SOD1", "char_span": [135, 139], "sem_type": "Gene or Genome", "tok_span": [31, 33], "new_tok_span": [40, 42]}, {"mention": "hSOD1", "char_span": [134, 139], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [30, 33], "new_tok_span": [37, 40]}], "new_text": "We recently showed that the first domain of human CCS ( hCCSD1 ) is responsible for <START=Pharmacologic Substance> copper <END=Pharmacologic Substance> transfer to its protein partner, human <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> SOD1 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> ( <START=Amino Acid, Peptide, or Protein> h <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome>SOD1 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> )."}, {"PMID": 20421509, "id": 11, "text": "Together these studies support a unique mode of inhibition in which phenothiazines disrupt the S100A4/myosin-IIA interaction by sequestering S100A4 via small molecule-induced oligomerization.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [68, 82], "name": "phenothiazines", "tok_span": [11, 15], "new_tok_span": [11, 15]}, {"ent_type": "GENE", "char_span": [95, 101], "name": "S100A4", "tok_span": [17, 21], "new_tok_span": [18, 22]}, {"ent_type": "GENE", "char_span": [102, 112], "name": "myosin-IIA", "tok_span": [22, 26], "new_tok_span": [24, 28]}, {"ent_type": "GENE", "char_span": [141, 147], "name": "S100A4", "tok_span": [30, 34], "new_tok_span": [33, 37]}], "relation_list": [{"subject": "phenothiazines", "sbj_char_span": [68, 82], "object": "S100A4", "obj_char_span": [95, 101], "rel_type": "inhibitor", "sbj_tok_span": [11, 15], "obj_tok_span": [17, 21], "new_sbj_tok_span": [11, 15], "new_obj_tok_span": [18, 22]}, {"subject": "phenothiazines", "sbj_char_span": [68, 82], "object": "myosin-IIA", "obj_char_span": [102, 112], "rel_type": "inhibitor", "sbj_tok_span": [11, 15], "obj_tok_span": [22, 26], "new_sbj_tok_span": [11, 15], "new_obj_tok_span": [24, 28]}], "umls_entity_list": [{"mention": "S100A4", "char_span": [95, 101], "sem_type": "Gene or Genome", "tok_span": [17, 21], "new_tok_span": [18, 22]}, {"mention": "S100A4", "char_span": [141, 147], "sem_type": "Gene or Genome", "tok_span": [30, 34], "new_tok_span": [33, 37]}], "new_text": "Together these studies support a unique mode of inhibition in which phenothiazines disrupt the <START=Gene or Genome> S100A4 <END=Gene or Genome> / myosin - IIA interaction by sequestering <START=Gene or Genome> S100A4 <END=Gene or Genome> via small molecule - induced oligomerization."}, {"PMID": 9712175, "id": 7, "text": "Lintitript markedly increased postprandial plasma CCK release (P<0.001) while distinctly reducing postprandial PP levels (P<0.01) as compared to placebo.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 10], "name": "Lintitript", "tok_span": [0, 4], "new_tok_span": [1, 5]}, {"ent_type": "GENE", "char_span": [50, 53], "name": "CCK", "tok_span": [10, 12], "new_tok_span": [13, 15]}, {"ent_type": "GENE", "char_span": [111, 113], "name": "PP", "tok_span": [27, 28], "new_tok_span": [33, 34]}], "relation_list": [{"subject": "Lintitript", "sbj_char_span": [0, 10], "object": "CCK", "obj_char_span": [50, 53], "rel_type": "regulator", "sbj_tok_span": [0, 4], "obj_tok_span": [10, 12], "new_sbj_tok_span": [1, 5], "new_obj_tok_span": [13, 15]}, {"subject": "Lintitript", "sbj_char_span": [0, 10], "object": "PP", "obj_char_span": [111, 113], "rel_type": "regulator", "sbj_tok_span": [0, 4], "obj_tok_span": [27, 28], "new_sbj_tok_span": [1, 5], "new_obj_tok_span": [33, 34]}], "umls_entity_list": [{"mention": "Lintitript", "char_span": [0, 10], "sem_type": "Pharmacologic Substance", "tok_span": [0, 4], "new_tok_span": [1, 5]}, {"mention": "CCK", "char_span": [50, 53], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [10, 12], "new_tok_span": [13, 15]}, {"mention": "PP", "char_span": [111, 113], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [27, 28], "new_tok_span": [33, 34]}, {"mention": "PP", "char_span": [111, 113], "sem_type": "Gene or Genome", "tok_span": [27, 28], "new_tok_span": [33, 34]}], "new_text": "<START=Pharmacologic Substance> Lintitript <END=Pharmacologic Substance> markedly increased postprandial plasma <START=Amino Acid, Peptide, or Protein> CCK <END=Amino Acid, Peptide, or Protein> release ( P < 0. 001 ) while distinctly reducing postprandial <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> PP <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> levels ( P < 0. 01 ) as compared to placebo."}, {"PMID": 23266505, "id": 0, "text": "Activation of an apoptotic signal transduction pathway involved in the upregulation of calpain and apoptosis-inducing factor in aldosterone-induced primary cultured cardiomyocytes.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [128, 139], "name": "aldosterone", "tok_span": [20, 22], "new_tok_span": [26, 28]}, {"ent_type": "GENE", "char_span": [87, 94], "name": "calpain", "tok_span": [12, 14], "new_tok_span": [13, 15]}, {"ent_type": "GENE", "char_span": [99, 124], "name": "apoptosis-inducing factor", "tok_span": [15, 19], "new_tok_span": [19, 23]}], "relation_list": [{"subject": "aldosterone", "sbj_char_span": [128, 139], "object": "calpain", "obj_char_span": [87, 94], "rel_type": "regulator", "sbj_tok_span": [20, 22], "obj_tok_span": [12, 14], "new_sbj_tok_span": [26, 28], "new_obj_tok_span": [13, 15]}, {"subject": "aldosterone", "sbj_char_span": [128, 139], "object": "apoptosis-inducing factor", "obj_char_span": [99, 124], "rel_type": "regulator", "sbj_tok_span": [20, 22], "obj_tok_span": [15, 19], "new_sbj_tok_span": [26, 28], "new_obj_tok_span": [19, 23]}], "umls_entity_list": [{"mention": "calpain", "char_span": [87, 94], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [12, 14], "new_tok_span": [13, 15]}, {"mention": "apoptosis", "char_span": [99, 108], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [15, 16], "new_tok_span": [19, 20]}, {"mention": "apoptosis-inducing factor", "char_span": [99, 124], "sem_type": "Gene or Genome", "tok_span": [15, 19], "new_tok_span": [19, 23]}], "new_text": "Activation of an apoptotic signal transduction pathway involved in the upregulation of <START=Amino Acid, Peptide, or Protein> calpain <END=Amino Acid, Peptide, or Protein> and <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> apoptosis <END=Amino Acid, Peptide, or Protein> - inducing factor <END=Gene or Genome> in aldosterone - induced primary cultured cardiomyocytes."}, {"PMID": 16846546, "id": 2, "text": "METHODS: Cyclooxygenase activity and selectivity was determined in vitro by measuring prostaglandin E(2) (PGE(2)) production following incubation of varying concentrations of NSAID with human recombinant COX-1 or COX-2 and arachidonic acid.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [86, 104], "name": "prostaglandin E(2)", "tok_span": [16, 21], "new_tok_span": [16, 21]}, {"ent_type": "CHEMICAL", "char_span": [106, 112], "name": "PGE(2)", "tok_span": [22, 26], "new_tok_span": [22, 26]}, {"ent_type": "CHEMICAL", "char_span": [223, 239], "name": "arachidonic acid", "tok_span": [47, 51], "new_tok_span": [49, 53]}, {"ent_type": "GENE", "char_span": [9, 23], "name": "Cyclooxygenase", "tok_span": [2, 7], "new_tok_span": [2, 7]}, {"ent_type": "GENE", "char_span": [186, 209], "name": "human recombinant COX-1", "tok_span": [37, 42], "new_tok_span": [39, 44]}, {"ent_type": "GENE", "char_span": [213, 218], "name": "COX-2", "tok_span": [43, 46], "new_tok_span": [45, 48]}], "relation_list": [{"subject": "prostaglandin E(2)", "sbj_char_span": [86, 104], "object": "Cyclooxygenase", "obj_char_span": [9, 23], "rel_type": "product or substrate", "sbj_tok_span": [16, 21], "obj_tok_span": [2, 7], "new_sbj_tok_span": [16, 21], "new_obj_tok_span": [2, 7]}, {"subject": "PGE(2)", "sbj_char_span": [106, 112], "object": "Cyclooxygenase", "obj_char_span": [9, 23], "rel_type": "product or substrate", "sbj_tok_span": [22, 26], "obj_tok_span": [2, 7], "new_sbj_tok_span": [22, 26], "new_obj_tok_span": [2, 7]}], "umls_entity_list": [{"mention": "NSAID", "char_span": [175, 180], "sem_type": "Pharmacologic Substance", "tok_span": [34, 36], "new_tok_span": [35, 37]}], "new_text": "METHODS : Cyclooxygenase activity and selectivity was determined in vitro by measuring prostaglandin E ( 2 ) ( PGE ( 2 ) ) production following incubation of varying concentrations of <START=Pharmacologic Substance> NSAID <END=Pharmacologic Substance> with human recombinant COX - 1 or COX - 2 and arachidonic acid."}, {"PMID": 18068977, "id": 1, "text": "Dipeptidyl peptidase-IV (DPP-IV) is an enzyme responsible for the inactivation of the glucoregulatory incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). In this report, we show that the hypolipidemic agent atorvastatin is a competitive inhibitor of porcine DPP-IV in vitro, with K(i)=57.8+/-2.3 microM.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [261, 273], "name": "atorvastatin", "tok_span": [63, 66], "new_tok_span": [72, 75]}, {"ent_type": "GENE", "char_span": [0, 23], "name": "Dipeptidyl peptidase-IV", "tok_span": [0, 8], "new_tok_span": [1, 9]}, {"ent_type": "GENE", "char_span": [102, 119], "name": "incretin hormones", "tok_span": [25, 28], "new_tok_span": [28, 31]}, {"ent_type": "GENE", "char_span": [120, 143], "name": "glucagon-like peptide-1", "tok_span": [28, 34], "new_tok_span": [33, 39]}, {"ent_type": "GENE", "char_span": [145, 150], "name": "GLP-1", "tok_span": [35, 38], "new_tok_span": [41, 44]}, {"ent_type": "GENE", "char_span": [156, 200], "name": "glucose-dependent insulinotropic polypeptide", "tok_span": [40, 46], "new_tok_span": [46, 52]}, {"ent_type": "GENE", "char_span": [202, 205], "name": "GIP", "tok_span": [47, 49], "new_tok_span": [53, 55]}, {"ent_type": "GENE", "char_span": [25, 31], "name": "DPP-IV", "tok_span": [9, 12], "new_tok_span": [11, 14]}, {"ent_type": "GENE", "char_span": [304, 318], "name": "porcine DPP-IV", "tok_span": [71, 75], "new_tok_span": [81, 85]}], "relation_list": [{"subject": "atorvastatin", "sbj_char_span": [261, 273], "object": "porcine DPP-IV", "obj_char_span": [304, 318], "rel_type": "inhibitor", "sbj_tok_span": [63, 66], "obj_tok_span": [71, 75], "new_sbj_tok_span": [72, 75], "new_obj_tok_span": [81, 85]}], "umls_entity_list": [{"mention": "incretin hormone", "char_span": [102, 118], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [25, 28], "new_tok_span": [28, 31]}, {"mention": "glucagon-like", "char_span": [120, 133], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [28, 31], "new_tok_span": [33, 36]}, {"mention": "hypolipidemic agent", "char_span": [241, 260], "sem_type": "Pharmacologic Substance", "tok_span": [59, 63], "new_tok_span": [66, 70]}, {"mention": "atorvastatin", "char_span": [261, 273], "sem_type": "Pharmacologic Substance", "tok_span": [63, 66], "new_tok_span": [72, 75]}, {"mention": "Dipeptidyl", "char_span": [0, 10], "sem_type": "Pharmacologic Substance", "tok_span": [0, 4], "new_tok_span": [1, 5]}], "new_text": "<START=Pharmacologic Substance> Dipeptidyl <END=Pharmacologic Substance> peptidase - IV ( DPP - IV ) is an enzyme responsible for the inactivation of the glucoregulatory <START=Amino Acid, Peptide, or Protein> incretin hormones <END=Amino Acid, Peptide, or Protein> <START=Amino Acid, Peptide, or Protein> glucagon - like <END=Amino Acid, Peptide, or Protein> peptide - 1 ( GLP - 1 ) and glucose - dependent insulinotropic polypeptide ( GIP ). In this report, we show that the <START=Pharmacologic Substance> hypolipidemic agent <END=Pharmacologic Substance> <START=Pharmacologic Substance> atorvastatin <END=Pharmacologic Substance> is a competitive inhibitor of porcine DPP - IV in vitro, with K ( i ) = 57. 8 + / - 2. 3 microM."}, {"PMID": 22445601, "id": 0, "text": "Differentiating the roles of mGlu2 and mGlu3 receptors using LY541850, an mGlu2 agonist/mGlu3 antagonist.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [61, 69], "name": "LY541850", "tok_span": [15, 19], "new_tok_span": [17, 21]}, {"ent_type": "GENE", "char_span": [29, 34], "name": "mGlu2", "tok_span": [6, 9], "new_tok_span": [6, 9]}, {"ent_type": "GENE", "char_span": [39, 44], "name": "mGlu3", "tok_span": [10, 13], "new_tok_span": [11, 14]}, {"ent_type": "GENE", "char_span": [74, 79], "name": "mGlu2", "tok_span": [21, 24], "new_tok_span": [23, 26]}, {"ent_type": "GENE", "char_span": [88, 93], "name": "mGlu3", "tok_span": [26, 29], "new_tok_span": [29, 32]}], "relation_list": [{"subject": "LY541850", "sbj_char_span": [61, 69], "object": "mGlu2", "obj_char_span": [74, 79], "rel_type": "agonist or antagonist", "sbj_tok_span": [15, 19], "obj_tok_span": [21, 24], "new_sbj_tok_span": [17, 21], "new_obj_tok_span": [23, 26]}, {"subject": "LY541850", "sbj_char_span": [61, 69], "object": "mGlu3", "obj_char_span": [88, 93], "rel_type": "agonist or antagonist", "sbj_tok_span": [15, 19], "obj_tok_span": [26, 29], "new_sbj_tok_span": [17, 21], "new_obj_tok_span": [29, 32]}], "umls_entity_list": [{"mention": "mGlu3", "char_span": [39, 44], "sem_type": "Gene or Genome", "tok_span": [10, 13], "new_tok_span": [11, 14]}, {"mention": "mGlu3", "char_span": [88, 93], "sem_type": "Gene or Genome", "tok_span": [26, 29], "new_tok_span": [29, 32]}], "new_text": "Differentiating the roles of mGlu2 and <START=Gene or Genome> mGlu3 <END=Gene or Genome> receptors using LY541850, an mGlu2 agonist / <START=Gene or Genome> mGlu3 <END=Gene or Genome> antagonist."}, {"PMID": 23497227, "id": 0, "text": "Synthesis and in vitro evaluation of N-Aryl pyrido-quinazolines derivatives as potent EGFR inhibitors.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [37, 63], "name": "N-Aryl pyrido-quinazolines", "tok_span": [6, 16], "new_tok_span": [6, 16]}, {"ent_type": "GENE", "char_span": [86, 90], "name": "EGFR", "tok_span": [19, 20], "new_tok_span": [21, 22]}], "relation_list": [{"subject": "N-Aryl pyrido-quinazolines", "sbj_char_span": [37, 63], "object": "EGFR", "obj_char_span": [86, 90], "rel_type": "inhibitor", "sbj_tok_span": [6, 16], "obj_tok_span": [19, 20], "new_sbj_tok_span": [6, 16], "new_obj_tok_span": [21, 22]}], "umls_entity_list": [{"mention": "quinazolines", "char_span": [51, 63], "sem_type": "Organic Chemical", "tok_span": [13, 16], "new_tok_span": [14, 17]}], "new_text": "Synthesis and in vitro evaluation of N - Aryl pyrido - <START=Organic Chemical> quinazolines <END=Organic Chemical> derivatives as potent EGFR inhibitors."}, {"PMID": 11264758, "id": 2, "text": "Pranlukast is a new, orally active, selective inhibitor of CysLt1 leukotriene receptor.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [66, 77], "name": "leukotriene", "tok_span": [19, 22], "new_tok_span": [22, 25]}, {"ent_type": "CHEMICAL", "char_span": [0, 10], "name": "Pranlukast", "tok_span": [0, 5], "new_tok_span": [0, 5]}, {"ent_type": "GENE", "char_span": [59, 65], "name": "CysLt1", "tok_span": [15, 19], "new_tok_span": [16, 20]}, {"ent_type": "GENE", "char_span": [66, 86], "name": "leukotriene receptor", "tok_span": [19, 23], "new_tok_span": [22, 26]}], "relation_list": [{"subject": "leukotriene", "sbj_char_span": [66, 77], "object": "CysLt1", "obj_char_span": [59, 65], "rel_type": "regulator", "sbj_tok_span": [19, 22], "obj_tok_span": [15, 19], "new_sbj_tok_span": [22, 25], "new_obj_tok_span": [16, 20]}, {"subject": "leukotriene", "sbj_char_span": [66, 77], "object": "leukotriene receptor", "obj_char_span": [66, 86], "rel_type": "regulator", "sbj_tok_span": [19, 22], "obj_tok_span": [19, 23], "new_sbj_tok_span": [22, 25], "new_obj_tok_span": [22, 26]}, {"subject": "Pranlukast", "sbj_char_span": [0, 10], "object": "CysLt1", "obj_char_span": [59, 65], "rel_type": "inhibitor", "sbj_tok_span": [0, 5], "obj_tok_span": [15, 19], "new_sbj_tok_span": [0, 5], "new_obj_tok_span": [16, 20]}, {"subject": "Pranlukast", "sbj_char_span": [0, 10], "object": "leukotriene receptor", "obj_char_span": [66, 86], "rel_type": "inhibitor", "sbj_tok_span": [0, 5], "obj_tok_span": [19, 23], "new_sbj_tok_span": [0, 5], "new_obj_tok_span": [22, 26]}], "umls_entity_list": [{"mention": "CysLt1", "char_span": [59, 65], "sem_type": "Gene or Genome", "tok_span": [15, 19], "new_tok_span": [16, 20]}, {"mention": "leukotriene", "char_span": [66, 77], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [19, 22], "new_tok_span": [22, 25]}], "new_text": "Pranlukast is a new, orally active, selective inhibitor of <START=Gene or Genome> CysLt1 <END=Gene or Genome> <START=Amino Acid, Peptide, or Protein> leukotriene <END=Amino Acid, Peptide, or Protein> receptor."}, {"PMID": 16434489, "id": 5, "text": "Additionally, dasatinib leads to growth inhibition of a KITD816V-harboring human masto-cytosis cell line.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [14, 23], "name": "dasatinib", "tok_span": [2, 4], "new_tok_span": [2, 4]}, {"ent_type": "GENE", "char_span": [56, 59], "name": "KIT", "tok_span": [10, 12], "new_tok_span": [10, 12]}, {"ent_type": "GENE", "char_span": [59, 64], "name": "D816V", "tok_span": [11, 15], "new_tok_span": [11, 15]}], "relation_list": [{"subject": "dasatinib", "sbj_char_span": [14, 23], "object": "KIT", "obj_char_span": [56, 59], "rel_type": "inhibitor", "sbj_tok_span": [2, 4], "obj_tok_span": [10, 12], "new_sbj_tok_span": [2, 4], "new_obj_tok_span": [10, 12]}, {"subject": "dasatinib", "sbj_char_span": [14, 23], "object": "D816V", "obj_char_span": [59, 64], "rel_type": "inhibitor", "sbj_tok_span": [2, 4], "obj_tok_span": [11, 15], "new_sbj_tok_span": [2, 4], "new_obj_tok_span": [11, 15]}], "umls_entity_list": [], "new_text": "Additionally, dasatinib leads to growth inhibition of a KITD816V - harboring human masto - cytosis cell line."}, {"PMID": 7773533, "id": 2, "text": "Incubation of rat aortic membranes with the irreversible alpha 1B-adrenoceptor antagonist, chloroethylclonidine (CEC: 10 microM) did not change the KD of [3H]-prazosin binding in comparison to untreated membranes, but reduced by 88% the total number of binding sites (Bmax). 3.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [91, 111], "name": "chloroethylclonidine", "tok_span": [18, 26], "new_tok_span": [19, 27]}, {"ent_type": "CHEMICAL", "char_span": [113, 116], "name": "CEC", "tok_span": [27, 29], "new_tok_span": [29, 31]}, {"ent_type": "CHEMICAL", "char_span": [154, 167], "name": "[3H]-prazosin", "tok_span": [40, 48], "new_tok_span": [44, 52]}, {"ent_type": "GENE", "char_span": [57, 78], "name": "alpha 1B-adrenoceptor", "tok_span": [9, 16], "new_tok_span": [9, 16]}], "relation_list": [{"subject": "chloroethylclonidine", "sbj_char_span": [91, 111], "object": "alpha 1B-adrenoceptor", "obj_char_span": [57, 78], "rel_type": "agonist or antagonist", "sbj_tok_span": [18, 26], "obj_tok_span": [9, 16], "new_sbj_tok_span": [19, 27], "new_obj_tok_span": [9, 16]}, {"subject": "CEC", "sbj_char_span": [113, 116], "object": "alpha 1B-adrenoceptor", "obj_char_span": [57, 78], "rel_type": "agonist or antagonist", "sbj_tok_span": [27, 29], "obj_tok_span": [9, 16], "new_sbj_tok_span": [29, 31], "new_obj_tok_span": [9, 16]}, {"subject": "[3H]-prazosin", "sbj_char_span": [154, 167], "object": "alpha 1B-adrenoceptor", "obj_char_span": [57, 78], "rel_type": "regulator", "sbj_tok_span": [40, 48], "obj_tok_span": [9, 16], "new_sbj_tok_span": [44, 52], "new_obj_tok_span": [9, 16]}], "umls_entity_list": [{"mention": "chloroethylclonidine", "char_span": [91, 111], "sem_type": "Pharmacologic Substance", "tok_span": [18, 26], "new_tok_span": [19, 27]}, {"mention": "KD", "char_span": [148, 150], "sem_type": "Gene or Genome", "tok_span": [38, 39], "new_tok_span": [41, 42]}, {"mention": "prazosin", "char_span": [159, 167], "sem_type": "Pharmacologic Substance", "tok_span": [45, 48], "new_tok_span": [50, 53]}], "new_text": "Incubation of rat aortic membranes with the irreversible alpha 1B - adrenoceptor antagonist, <START=Pharmacologic Substance> chloroethylclonidine <END=Pharmacologic Substance> ( CEC : 10 microM ) did not change the <START=Gene or Genome> KD <END=Gene or Genome> of [ 3H ] - <START=Pharmacologic Substance> prazosin <END=Pharmacologic Substance> binding in comparison to untreated membranes, but reduced by 88 % the total number of binding sites ( Bmax ). 3."}, {"PMID": 12086935, "id": 3, "text": "We recently reported that AMPK is activated by metformin in cultured rat hepatocytes, mediating the inhibitory effects of the drug on hepatic glucose production.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [47, 56], "name": "metformin", "tok_span": [8, 9], "new_tok_span": [8, 9]}, {"ent_type": "CHEMICAL", "char_span": [142, 149], "name": "glucose", "tok_span": [23, 24], "new_tok_span": [23, 24]}, {"ent_type": "GENE", "char_span": [26, 30], "name": "AMPK", "tok_span": [4, 5], "new_tok_span": [4, 5]}], "relation_list": [{"subject": "metformin", "sbj_char_span": [47, 56], "object": "AMPK", "obj_char_span": [26, 30], "rel_type": "activator", "sbj_tok_span": [8, 9], "obj_tok_span": [4, 5], "new_sbj_tok_span": [8, 9], "new_obj_tok_span": [4, 5]}], "umls_entity_list": [], "new_text": "We recently reported that AMPK is activated by metformin in cultured rat hepatocytes, mediating the inhibitory effects of the drug on hepatic glucose production."}, {"PMID": 23597506, "id": 9, "text": "However, enzymes contributing to oxidative metabolism of anandamide, namely cyclooxygenase-1 and Cyp2D6, were increased in the brain of aged mice, possibly enhancing the oxidative breakdown of anandamide.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [57, 67], "name": "anandamide", "tok_span": [8, 11], "new_tok_span": [9, 12]}, {"ent_type": "CHEMICAL", "char_span": [193, 203], "name": "anandamide", "tok_span": [38, 41], "new_tok_span": [43, 46]}, {"ent_type": "GENE", "char_span": [76, 92], "name": "cyclooxygenase-1", "tok_span": [13, 17], "new_tok_span": [16, 20]}, {"ent_type": "GENE", "char_span": [97, 103], "name": "Cyp2D6", "tok_span": [18, 22], "new_tok_span": [22, 26]}], "relation_list": [{"subject": "anandamide", "sbj_char_span": [57, 67], "object": "cyclooxygenase-1", "obj_char_span": [76, 92], "rel_type": "product or substrate", "sbj_tok_span": [8, 11], "obj_tok_span": [13, 17], "new_sbj_tok_span": [9, 12], "new_obj_tok_span": [16, 20]}, {"subject": "anandamide", "sbj_char_span": [57, 67], "object": "Cyp2D6", "obj_char_span": [97, 103], "rel_type": "product or substrate", "sbj_tok_span": [8, 11], "obj_tok_span": [18, 22], "new_sbj_tok_span": [9, 12], "new_obj_tok_span": [22, 26]}, {"subject": "anandamide", "sbj_char_span": [193, 203], "object": "cyclooxygenase-1", "obj_char_span": [76, 92], "rel_type": "product or substrate", "sbj_tok_span": [38, 41], "obj_tok_span": [13, 17], "new_sbj_tok_span": [43, 46], "new_obj_tok_span": [16, 20]}, {"subject": "anandamide", "sbj_char_span": [193, 203], "object": "Cyp2D6", "obj_char_span": [97, 103], "rel_type": "product or substrate", "sbj_tok_span": [38, 41], "obj_tok_span": [18, 22], "new_sbj_tok_span": [43, 46], "new_obj_tok_span": [22, 26]}], "umls_entity_list": [{"mention": "anandamide", "char_span": [57, 67], "sem_type": "Organic Chemical", "tok_span": [8, 11], "new_tok_span": [9, 12]}, {"mention": "anandamide", "char_span": [193, 203], "sem_type": "Organic Chemical", "tok_span": [38, 41], "new_tok_span": [43, 46]}, {"mention": "cyclooxygenase-1", "char_span": [76, 92], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [13, 17], "new_tok_span": [16, 20]}], "new_text": "However, enzymes contributing to oxidative metabolism of <START=Organic Chemical> anandamide <END=Organic Chemical>, namely <START=Amino Acid, Peptide, or Protein> cyclooxygenase - 1 <END=Amino Acid, Peptide, or Protein> and Cyp2D6, were increased in the brain of aged mice, possibly enhancing the oxidative breakdown of <START=Organic Chemical> anandamide <END=Organic Chemical>."}, {"PMID": 12727196, "id": 2, "text": "Purified PAOh1/SMO oxidizes both spermine (K(m)=1.6 microM) and N(1)-acetylspermine (K(m)=51 microM), but does not oxidize spermidine.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [33, 41], "name": "spermine", "tok_span": [12, 14], "new_tok_span": [18, 20]}, {"ent_type": "CHEMICAL", "char_span": [64, 83], "name": "N(1)-acetylspermine", "tok_span": [27, 36], "new_tok_span": [33, 42]}, {"ent_type": "CHEMICAL", "char_span": [123, 133], "name": "spermidine", "tok_span": [52, 54], "new_tok_span": [58, 60]}, {"ent_type": "GENE", "char_span": [9, 14], "name": "PAOh1", "tok_span": [2, 6], "new_tok_span": [3, 7]}, {"ent_type": "GENE", "char_span": [15, 18], "name": "SMO", "tok_span": [7, 9], "new_tok_span": [11, 13]}], "relation_list": [{"subject": "spermine", "sbj_char_span": [33, 41], "object": "PAOh1", "obj_char_span": [9, 14], "rel_type": "product or substrate", "sbj_tok_span": [12, 14], "obj_tok_span": [2, 6], "new_sbj_tok_span": [18, 20], "new_obj_tok_span": [3, 7]}, {"subject": "spermine", "sbj_char_span": [33, 41], "object": "SMO", "obj_char_span": [15, 18], "rel_type": "product or substrate", "sbj_tok_span": [12, 14], "obj_tok_span": [7, 9], "new_sbj_tok_span": [18, 20], "new_obj_tok_span": [11, 13]}, {"subject": "N(1)-acetylspermine", "sbj_char_span": [64, 83], "object": "SMO", "obj_char_span": [15, 18], "rel_type": "product or substrate", "sbj_tok_span": [27, 36], "obj_tok_span": [7, 9], "new_sbj_tok_span": [33, 42], "new_obj_tok_span": [11, 13]}, {"subject": "N(1)-acetylspermine", "sbj_char_span": [64, 83], "object": "PAOh1", "obj_char_span": [9, 14], "rel_type": "product or substrate", "sbj_tok_span": [27, 36], "obj_tok_span": [2, 6], "new_sbj_tok_span": [33, 42], "new_obj_tok_span": [3, 7]}], "umls_entity_list": [{"mention": "PAOh1", "char_span": [9, 14], "sem_type": "Gene or Genome", "tok_span": [2, 6], "new_tok_span": [3, 7]}, {"mention": "SMO", "char_span": [15, 18], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [7, 9], "new_tok_span": [11, 13]}, {"mention": "SMO", "char_span": [15, 18], "sem_type": "Gene or Genome", "tok_span": [7, 9], "new_tok_span": [11, 13]}], "new_text": "Purified <START=Gene or Genome> PAOh1 <END=Gene or Genome> / <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> SMO <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> oxidizes both spermine ( K ( m ) = 1. 6 microM ) and N ( 1 ) - acetylspermine ( K ( m ) = 51 microM ), but does not oxidize spermidine."}, {"PMID": 16343532, "id": 0, "text": "Crystal structures of protein phosphatase-1 bound to motuporin and dihydromicrocystin-LA: elucidation of the mechanism of enzyme inhibition by cyanobacterial toxins.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [53, 62], "name": "motuporin", "tok_span": [9, 13], "new_tok_span": [12, 16]}, {"ent_type": "CHEMICAL", "char_span": [67, 88], "name": "dihydromicrocystin-LA", "tok_span": [14, 22], "new_tok_span": [18, 26]}, {"ent_type": "GENE", "char_span": [22, 43], "name": "protein phosphatase-1", "tok_span": [3, 7], "new_tok_span": [4, 8]}], "relation_list": [{"subject": "motuporin", "sbj_char_span": [53, 62], "object": "protein phosphatase-1", "obj_char_span": [22, 43], "rel_type": "regulator", "sbj_tok_span": [9, 13], "obj_tok_span": [3, 7], "new_sbj_tok_span": [12, 16], "new_obj_tok_span": [4, 8]}, {"subject": "dihydromicrocystin-LA", "sbj_char_span": [67, 88], "object": "protein phosphatase-1", "obj_char_span": [22, 43], "rel_type": "regulator", "sbj_tok_span": [14, 22], "obj_tok_span": [3, 7], "new_sbj_tok_span": [18, 26], "new_obj_tok_span": [4, 8]}], "umls_entity_list": [{"mention": "protein", "char_span": [22, 29], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [3, 4], "new_tok_span": [4, 5]}, {"mention": "motuporin", "char_span": [53, 62], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [9, 13], "new_tok_span": [12, 16]}, {"mention": "LA", "char_span": [86, 88], "sem_type": "Pharmacologic Substance", "tok_span": [21, 22], "new_tok_span": [28, 29]}, {"mention": "LA", "char_span": [86, 88], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [21, 22], "new_tok_span": [28, 29]}, {"mention": "LA", "char_span": [86, 88], "sem_type": "Gene or Genome", "tok_span": [21, 22], "new_tok_span": [28, 29]}, {"mention": "cyanobacterial toxins", "char_span": [143, 164], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [32, 35], "new_tok_span": [43, 46]}], "new_text": "Crystal structures of <START=Amino Acid, Peptide, or Protein> protein <END=Amino Acid, Peptide, or Protein> phosphatase - 1 bound to <START=Amino Acid, Peptide, or Protein> motuporin <END=Amino Acid, Peptide, or Protein> and dihydromicrocystin - <START=Pharmacologic Substance> <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> LA <END=Pharmacologic Substance> <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> : elucidation of the mechanism of enzyme inhibition by <START=Amino Acid, Peptide, or Protein> cyanobacterial toxins <END=Amino Acid, Peptide, or Protein>."}, {"PMID": 17593236, "id": 0, "text": "Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [143, 154], "name": "glimepiride", "tok_span": [31, 35], "new_tok_span": [34, 38]}, {"ent_type": "CHEMICAL", "char_span": [167, 178], "name": "glimepiride", "tok_span": [38, 42], "new_tok_span": [43, 47]}, {"ent_type": "CHEMICAL", "char_span": [183, 192], "name": "metformin", "tok_span": [43, 44], "new_tok_span": [49, 50]}, {"ent_type": "CHEMICAL", "char_span": [61, 72], "name": "sitagliptin", "tok_span": [15, 19], "new_tok_span": [17, 21]}, {"ent_type": "GENE", "char_span": [27, 49], "name": "dipeptidyl peptidase-4", "tok_span": [5, 13], "new_tok_span": [6, 14]}], "relation_list": [{"subject": "sitagliptin", "sbj_char_span": [61, 72], "object": "dipeptidyl peptidase-4", "obj_char_span": [27, 49], "rel_type": "inhibitor", "sbj_tok_span": [15, 19], "obj_tok_span": [5, 13], "new_sbj_tok_span": [17, 21], "new_obj_tok_span": [6, 14]}], "umls_entity_list": [{"mention": "dipeptidyl", "char_span": [27, 37], "sem_type": "Pharmacologic Substance", "tok_span": [5, 9], "new_tok_span": [6, 10]}, {"mention": "glimepiride", "char_span": [143, 154], "sem_type": "Pharmacologic Substance", "tok_span": [31, 35], "new_tok_span": [34, 38]}, {"mention": "glimepiride", "char_span": [167, 178], "sem_type": "Pharmacologic Substance", "tok_span": [38, 42], "new_tok_span": [43, 47]}], "new_text": "Efficacy and safety of the <START=Pharmacologic Substance> dipeptidyl <END=Pharmacologic Substance> peptidase - 4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on <START=Pharmacologic Substance> glimepiride <END=Pharmacologic Substance> alone or on <START=Pharmacologic Substance> glimepiride <END=Pharmacologic Substance> and metformin."}, {"PMID": 18035186, "id": 6, "text": "Based on the results from those studies, we concluded that rasagiline PO QD, at the therapeutic dosage range of 0.5 to 1 rag/d, is effective and well tolerated and completely, selectively, and specifically inhibited MAO-B.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [59, 69], "name": "rasagiline", "tok_span": [11, 15], "new_tok_span": [12, 16]}, {"ent_type": "GENE", "char_span": [216, 221], "name": "MAO-B", "tok_span": [47, 51], "new_tok_span": [49, 53]}], "relation_list": [{"subject": "rasagiline", "sbj_char_span": [59, 69], "object": "MAO-B", "obj_char_span": [216, 221], "rel_type": "inhibitor", "sbj_tok_span": [11, 15], "obj_tok_span": [47, 51], "new_sbj_tok_span": [12, 16], "new_obj_tok_span": [49, 53]}], "umls_entity_list": [{"mention": "rasagiline", "char_span": [59, 69], "sem_type": "Pharmacologic Substance", "tok_span": [11, 15], "new_tok_span": [12, 16]}], "new_text": "Based on the results from those studies, we concluded that <START=Pharmacologic Substance> rasagiline <END=Pharmacologic Substance> PO QD, at the therapeutic dosage range of 0. 5 to 1 rag / d, is effective and well tolerated and completely, selectively, and specifically inhibited MAO - B."}, {"PMID": 23344974, "id": 6, "text": "The initial fragment hits were thoroughly validated biophysically by isothermal titration calorimetry (ITC) and NMR techniques and observed by X-ray crystallography to bind in a shallow surface pocket that is occupied in the native complex by the side chain of a phenylalanine from the conserved FxxA interaction motif found in BRCA2. This represents the first report of fragments or any small molecule binding at this protein-protein interaction site.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [263, 276], "name": "phenylalanine", "tok_span": [53, 55], "new_tok_span": [56, 58]}, {"ent_type": "GENE", "char_span": [296, 318], "name": "FxxA interaction motif", "tok_span": [58, 63], "new_tok_span": [62, 67]}, {"ent_type": "GENE", "char_span": [328, 333], "name": "BRCA2", "tok_span": [65, 67], "new_tok_span": [71, 73]}], "relation_list": [{"subject": "phenylalanine", "sbj_char_span": [263, 276], "object": "FxxA interaction motif", "obj_char_span": [296, 318], "rel_type": "part of", "sbj_tok_span": [53, 55], "obj_tok_span": [58, 63], "new_sbj_tok_span": [56, 58], "new_obj_tok_span": [62, 67]}, {"subject": "phenylalanine", "sbj_char_span": [263, 276], "object": "BRCA2", "obj_char_span": [328, 333], "rel_type": "part of", "sbj_tok_span": [53, 55], "obj_tok_span": [65, 67], "new_sbj_tok_span": [56, 58], "new_obj_tok_span": [71, 73]}], "umls_entity_list": [{"mention": "hits", "char_span": [21, 25], "sem_type": "Gene or Genome", "tok_span": [3, 4], "new_tok_span": [4, 5]}, {"mention": "phenylalanine", "char_span": [263, 276], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [53, 55], "new_tok_span": [56, 58]}, {"mention": "BRCA2", "char_span": [328, 333], "sem_type": "Gene or Genome", "tok_span": [65, 67], "new_tok_span": [71, 73]}, {"mention": "BRCA2", "char_span": [328, 333], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [65, 67], "new_tok_span": [71, 73]}], "new_text": "The initial fragment <START=Gene or Genome> hits <END=Gene or Genome> were thoroughly validated biophysically by isothermal titration calorimetry ( ITC ) and NMR techniques and observed by X - ray crystallography to bind in a shallow surface pocket that is occupied in the native complex by the side chain of a <START=Amino Acid, Peptide, or Protein> phenylalanine <END=Amino Acid, Peptide, or Protein> from the conserved FxxA interaction motif found in <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> BRCA2 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein>. This represents the first report of fragments or any small molecule binding at this protein - protein interaction site."}, {"PMID": 23220644, "id": 2, "text": "In previous study, we discovered multi-target drugs towards the AA metabolic network, among which a dual-target inhibitor (JMC08-4) for human nonpancreatic secretory phospholipase A(2) (hnps-PLA(2)) and human leukotriene A(4) hydrolase (LTA(4)H-h) was found.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [123, 130], "name": "JMC08-4", "tok_span": [24, 29], "new_tok_span": [25, 30]}, {"ent_type": "GENE", "char_span": [136, 184], "name": "human nonpancreatic secretory phospholipase A(2)", "tok_span": [31, 43], "new_tok_span": [33, 45]}, {"ent_type": "GENE", "char_span": [186, 197], "name": "hnps-PLA(2)", "tok_span": [44, 51], "new_tok_span": [47, 54]}, {"ent_type": "GENE", "char_span": [203, 235], "name": "human leukotriene A(4) hydrolase", "tok_span": [53, 64], "new_tok_span": [57, 68]}, {"ent_type": "GENE", "char_span": [237, 246], "name": "LTA(4)H-h", "tok_span": [65, 73], "new_tok_span": [71, 79]}], "relation_list": [{"subject": "JMC08-4", "sbj_char_span": [123, 130], "object": "human nonpancreatic secretory phospholipase A(2)", "obj_char_span": [136, 184], "rel_type": "inhibitor", "sbj_tok_span": [24, 29], "obj_tok_span": [31, 43], "new_sbj_tok_span": [25, 30], "new_obj_tok_span": [33, 45]}, {"subject": "JMC08-4", "sbj_char_span": [123, 130], "object": "hnps-PLA(2)", "obj_char_span": [186, 197], "rel_type": "inhibitor", "sbj_tok_span": [24, 29], "obj_tok_span": [44, 51], "new_sbj_tok_span": [25, 30], "new_obj_tok_span": [47, 54]}, {"subject": "JMC08-4", "sbj_char_span": [123, 130], "object": "human leukotriene A(4) hydrolase", "obj_char_span": [203, 235], "rel_type": "inhibitor", "sbj_tok_span": [24, 29], "obj_tok_span": [53, 64], "new_sbj_tok_span": [25, 30], "new_obj_tok_span": [57, 68]}, {"subject": "JMC08-4", "sbj_char_span": [123, 130], "object": "LTA(4)H-h", "obj_char_span": [237, 246], "rel_type": "inhibitor", "sbj_tok_span": [24, 29], "obj_tok_span": [65, 73], "new_sbj_tok_span": [25, 30], "new_obj_tok_span": [71, 79]}], "umls_entity_list": [{"mention": "JMC08-4", "char_span": [123, 130], "sem_type": "Organic Chemical", "tok_span": [24, 29], "new_tok_span": [25, 30]}, {"mention": "hnp", "char_span": [186, 189], "sem_type": "Gene or Genome", "tok_span": [44, 46], "new_tok_span": [47, 49]}, {"mention": "leukotriene A(4) hydrolase", "char_span": [209, 235], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [54, 64], "new_tok_span": [59, 69]}], "new_text": "In previous study, we discovered multi - target drugs towards the AA metabolic network, among which a dual - target inhibitor ( <START=Organic Chemical> JMC08 - 4 <END=Organic Chemical> ) for human nonpancreatic secretory phospholipase A ( 2 ) ( <START=Gene or Genome> hnps <END=Gene or Genome> - PLA ( 2 ) ) and human <START=Amino Acid, Peptide, or Protein> leukotriene A ( 4 ) hydrolase <END=Amino Acid, Peptide, or Protein> ( LTA ( 4 ) H - h ) was found."}, {"PMID": 23600914, "id": 4, "text": "The efflux was suppressed by the addition of siRNA against ABCA1, but not by ABCG1 siRNA. To confirm the role of each transporter, we analyzed HEK293 cells stably expressing human ABCA1 or ABCG1; we clearly observed 24-OHC efflux in the presence of HDL, whereas efflux in the presence of apolipoprotein A-I was marginal.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [216, 222], "name": "24-OHC", "tok_span": [49, 53], "new_tok_span": [65, 69]}, {"ent_type": "GENE", "char_span": [249, 252], "name": "HDL", "tok_span": [58, 59], "new_tok_span": [74, 75]}, {"ent_type": "GENE", "char_span": [288, 306], "name": "apolipoprotein A-I", "tok_span": [66, 72], "new_tok_span": [84, 90]}, {"ent_type": "GENE", "char_span": [59, 64], "name": "ABCA1", "tok_span": [10, 13], "new_tok_span": [12, 15]}, {"ent_type": "GENE", "char_span": [77, 82], "name": "ABCG1", "tok_span": [17, 20], "new_tok_span": [23, 26]}, {"ent_type": "GENE", "char_span": [174, 185], "name": "human ABCA1", "tok_span": [37, 41], "new_tok_span": [45, 49]}, {"ent_type": "GENE", "char_span": [189, 194], "name": "ABCG1", "tok_span": [42, 45], "new_tok_span": [56, 59]}], "relation_list": [{"subject": "24-OHC", "sbj_char_span": [216, 222], "object": "human ABCA1", "obj_char_span": [174, 185], "rel_type": "product or substrate", "sbj_tok_span": [49, 53], "obj_tok_span": [37, 41], "new_sbj_tok_span": [65, 69], "new_obj_tok_span": [45, 49]}, {"subject": "24-OHC", "sbj_char_span": [216, 222], "object": "ABCG1", "obj_char_span": [189, 194], "rel_type": "product or substrate", "sbj_tok_span": [49, 53], "obj_tok_span": [42, 45], "new_sbj_tok_span": [65, 69], "new_obj_tok_span": [56, 59]}], "umls_entity_list": [{"mention": "ABCG1", "char_span": [77, 82], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [17, 20], "new_tok_span": [23, 26]}, {"mention": "ABCG1", "char_span": [189, 194], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [42, 45], "new_tok_span": [56, 59]}, {"mention": "ABCG1", "char_span": [77, 82], "sem_type": "Gene or Genome", "tok_span": [17, 20], "new_tok_span": [23, 26]}, {"mention": "ABCG1", "char_span": [189, 194], "sem_type": "Gene or Genome", "tok_span": [42, 45], "new_tok_span": [56, 59]}, {"mention": "ABCA1", "char_span": [59, 64], "sem_type": "Gene or Genome", "tok_span": [10, 13], "new_tok_span": [12, 15]}, {"mention": "ABCA1", "char_span": [180, 185], "sem_type": "Gene or Genome", "tok_span": [38, 41], "new_tok_span": [48, 51]}, {"mention": "ABCA1", "char_span": [59, 64], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [10, 13], "new_tok_span": [12, 15]}, {"mention": "ABCA1", "char_span": [180, 185], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [38, 41], "new_tok_span": [48, 51]}, {"mention": "apolipoprotein", "char_span": [288, 302], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [66, 69], "new_tok_span": [84, 87]}, {"mention": "apolipoprotein A-I", "char_span": [288, 306], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [66, 72], "new_tok_span": [84, 90]}], "new_text": "The efflux was suppressed by the addition of siRNA against <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> ABCA1 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein>, but not by <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> ABCG1 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> siRNA. To confirm the role of each transporter, we analyzed HEK293 cells stably expressing human <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> ABCA1 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> or <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> ABCG1 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> ; we clearly observed 24 - OHC efflux in the presence of HDL, whereas efflux in the presence of <START=Amino Acid, Peptide, or Protein> <START=Amino Acid, Peptide, or Protein> apolipoprotein <END=Amino Acid, Peptide, or Protein> A - I <END=Amino Acid, Peptide, or Protein> was marginal."}, {"PMID": 18620538, "id": 2, "text": "Apo-alpha-lactalbumin, obtained by treatment with EDTA, displays one binding site for fatty acids, the association constants for oleic and palmitic acids being 1.9.10(6) and 4.2.10(5) M(-1), respectively.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [50, 54], "name": "EDTA", "tok_span": [12, 13], "new_tok_span": [15, 16]}, {"ent_type": "CHEMICAL", "char_span": [86, 97], "name": "fatty acids", "tok_span": [19, 21], "new_tok_span": [23, 25]}, {"ent_type": "CHEMICAL", "char_span": [129, 153], "name": "oleic and palmitic acids", "tok_span": [26, 32], "new_tok_span": [30, 36]}, {"ent_type": "GENE", "char_span": [0, 21], "name": "Apo-alpha-lactalbumin", "tok_span": [0, 7], "new_tok_span": [1, 8]}], "relation_list": [{"subject": "fatty acids", "sbj_char_span": [86, 97], "object": "Apo-alpha-lactalbumin", "obj_char_span": [0, 21], "rel_type": "regulator", "sbj_tok_span": [19, 21], "obj_tok_span": [0, 7], "new_sbj_tok_span": [23, 25], "new_obj_tok_span": [1, 8]}, {"subject": "oleic and palmitic acids", "sbj_char_span": [129, 153], "object": "Apo-alpha-lactalbumin", "obj_char_span": [0, 21], "rel_type": "regulator", "sbj_tok_span": [26, 32], "obj_tok_span": [0, 7], "new_sbj_tok_span": [30, 36], "new_obj_tok_span": [1, 8]}], "umls_entity_list": [{"mention": "Apo-alpha-lactalbumin", "char_span": [0, 21], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [0, 7], "new_tok_span": [1, 8]}, {"mention": "EDTA", "char_span": [50, 54], "sem_type": "Pharmacologic Substance", "tok_span": [12, 13], "new_tok_span": [15, 16]}, {"mention": "palmitic", "char_span": [139, 147], "sem_type": "Organic Chemical", "tok_span": [29, 31], "new_tok_span": [34, 36]}], "new_text": "<START=Amino Acid, Peptide, or Protein> Apo - alpha - lactalbumin <END=Amino Acid, Peptide, or Protein>, obtained by treatment with <START=Pharmacologic Substance> EDTA <END=Pharmacologic Substance>, displays one binding site for fatty acids, the association constants for oleic and <START=Organic Chemical> palmitic <END=Organic Chemical> acids being 1. 9. 10 ( 6 ) and 4. 2. 10 ( 5 ) M ( - 1 ), respectively."}, {"PMID": 9607108, "id": 12, "text": "We propose that Cu(I) binds the type-1 copper ion-binding site in the A1 domain and provides the essential requirement for a stable interaction between the heavy and light chains.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [16, 21], "name": "Cu(I)", "tok_span": [3, 7], "new_tok_span": [3, 7]}, {"ent_type": "CHEMICAL", "char_span": [39, 45], "name": "copper", "tok_span": [12, 13], "new_tok_span": [13, 14]}, {"ent_type": "GENE", "char_span": [32, 62], "name": "type-1 copper ion-binding site", "tok_span": [9, 17], "new_tok_span": [9, 17]}, {"ent_type": "GENE", "char_span": [70, 79], "name": "A1 domain", "tok_span": [19, 22], "new_tok_span": [21, 24]}], "relation_list": [{"subject": "Cu(I)", "sbj_char_span": [16, 21], "object": "type-1 copper ion-binding site", "obj_char_span": [32, 62], "rel_type": "regulator", "sbj_tok_span": [3, 7], "obj_tok_span": [9, 17], "new_sbj_tok_span": [3, 7], "new_obj_tok_span": [9, 17]}, {"subject": "Cu(I)", "sbj_char_span": [16, 21], "object": "A1 domain", "obj_char_span": [70, 79], "rel_type": "regulator", "sbj_tok_span": [3, 7], "obj_tok_span": [19, 22], "new_sbj_tok_span": [3, 7], "new_obj_tok_span": [21, 24]}], "umls_entity_list": [{"mention": "copper", "char_span": [39, 45], "sem_type": "Pharmacologic Substance", "tok_span": [12, 13], "new_tok_span": [13, 14]}], "new_text": "We propose that Cu ( I ) binds the type - 1 <START=Pharmacologic Substance> copper <END=Pharmacologic Substance> ion - binding site in the A1 domain and provides the essential requirement for a stable interaction between the heavy and light chains."}, {"PMID": 16618126, "id": 5, "text": "The purified Atp8a1 is inactive in detergent micelles or in micelles containing phosphatidylcholine, phosphatidic acid, or phosphatidylinositol, is minimally activated by phosphatidylglycerol or phosphatidylethanolamine (PE), and is maximally activated by PS. The selectivity for PS is dependent upon multiple elements of the lipid structure.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [80, 99], "name": "phosphatidylcholine", "tok_span": [16, 18], "new_tok_span": [22, 24]}, {"ent_type": "CHEMICAL", "char_span": [101, 118], "name": "phosphatidic acid", "tok_span": [19, 23], "new_tok_span": [25, 29]}, {"ent_type": "CHEMICAL", "char_span": [123, 143], "name": "phosphatidylinositol", "tok_span": [25, 27], "new_tok_span": [32, 34]}, {"ent_type": "CHEMICAL", "char_span": [171, 191], "name": "phosphatidylglycerol", "tok_span": [32, 34], "new_tok_span": [41, 43]}, {"ent_type": "CHEMICAL", "char_span": [195, 219], "name": "phosphatidylethanolamine", "tok_span": [35, 38], "new_tok_span": [47, 50]}, {"ent_type": "CHEMICAL", "char_span": [221, 223], "name": "PE", "tok_span": [39, 40], "new_tok_span": [53, 54]}, {"ent_type": "CHEMICAL", "char_span": [256, 258], "name": "PS", "tok_span": [47, 48], "new_tok_span": [63, 64]}, {"ent_type": "CHEMICAL", "char_span": [280, 282], "name": "PS", "tok_span": [52, 53], "new_tok_span": [72, 73]}, {"ent_type": "GENE", "char_span": [13, 19], "name": "Atp8a1", "tok_span": [2, 7], "new_tok_span": [3, 8]}], "relation_list": [{"subject": "phosphatidylglycerol", "sbj_char_span": [171, 191], "object": "Atp8a1", "obj_char_span": [13, 19], "rel_type": "activator", "sbj_tok_span": [32, 34], "obj_tok_span": [2, 7], "new_sbj_tok_span": [41, 43], "new_obj_tok_span": [3, 8]}, {"subject": "phosphatidylethanolamine", "sbj_char_span": [195, 219], "object": "Atp8a1", "obj_char_span": [13, 19], "rel_type": "activator", "sbj_tok_span": [35, 38], "obj_tok_span": [2, 7], "new_sbj_tok_span": [47, 50], "new_obj_tok_span": [3, 8]}, {"subject": "PE", "sbj_char_span": [221, 223], "object": "Atp8a1", "obj_char_span": [13, 19], "rel_type": "activator", "sbj_tok_span": [39, 40], "obj_tok_span": [2, 7], "new_sbj_tok_span": [53, 54], "new_obj_tok_span": [3, 8]}, {"subject": "PS", "sbj_char_span": [256, 258], "object": "Atp8a1", "obj_char_span": [13, 19], "rel_type": "activator", "sbj_tok_span": [47, 48], "obj_tok_span": [2, 7], "new_sbj_tok_span": [63, 64], "new_obj_tok_span": [3, 8]}], "umls_entity_list": [{"mention": "Atp8a1", "char_span": [13, 19], "sem_type": "Gene or Genome", "tok_span": [2, 7], "new_tok_span": [3, 8]}, {"mention": "micelles", "char_span": [45, 53], "sem_type": "Organic Chemical", "tok_span": [11, 12], "new_tok_span": [14, 15]}, {"mention": "micelles", "char_span": [60, 68], "sem_type": "Organic Chemical", "tok_span": [14, 15], "new_tok_span": [19, 20]}, {"mention": "phosphatidylinositol", "char_span": [123, 143], "sem_type": "Organic Chemical", "tok_span": [25, 27], "new_tok_span": [32, 34]}, {"mention": "phosphatidylglycerol", "char_span": [171, 191], "sem_type": "Organic Chemical", "tok_span": [32, 34], "new_tok_span": [41, 43]}, {"mention": "phosphatidylethanolamine", "char_span": [195, 219], "sem_type": "Organic Chemical", "tok_span": [35, 38], "new_tok_span": [47, 50]}, {"mention": "phosphatidylethanolamine", "char_span": [195, 219], "sem_type": "Pharmacologic Substance", "tok_span": [35, 38], "new_tok_span": [47, 50]}, {"mention": "PS", "char_span": [256, 258], "sem_type": "Organic Chemical", "tok_span": [47, 48], "new_tok_span": [63, 64]}, {"mention": "PS", "char_span": [280, 282], "sem_type": "Organic Chemical", "tok_span": [52, 53], "new_tok_span": [72, 73]}, {"mention": "PS", "char_span": [256, 258], "sem_type": "Gene or Genome", "tok_span": [47, 48], "new_tok_span": [63, 64]}, {"mention": "PS", "char_span": [280, 282], "sem_type": "Gene or Genome", "tok_span": [52, 53], "new_tok_span": [72, 73]}, {"mention": "lipid", "char_span": [326, 331], "sem_type": "Organic Chemical", "tok_span": [60, 61], "new_tok_span": [83, 84]}], "new_text": "The purified <START=Gene or Genome> Atp8a1 <END=Gene or Genome> is inactive in detergent <START=Organic Chemical> micelles <END=Organic Chemical> or in <START=Organic Chemical> micelles <END=Organic Chemical> containing phosphatidylcholine, phosphatidic acid, or <START=Organic Chemical> phosphatidylinositol <END=Organic Chemical>, is minimally activated by <START=Organic Chemical> phosphatidylglycerol <END=Organic Chemical> or <START=Organic Chemical> <START=Pharmacologic Substance> phosphatidylethanolamine <END=Organic Chemical> <END=Pharmacologic Substance> ( PE ), and is maximally activated by <START=Organic Chemical> <START=Gene or Genome> PS <END=Organic Chemical> <END=Gene or Genome>. The selectivity for <START=Organic Chemical> <START=Gene or Genome> PS <END=Organic Chemical> <END=Gene or Genome> is dependent upon multiple elements of the <START=Organic Chemical> lipid <END=Organic Chemical> structure."}, {"PMID": 11166732, "id": 1, "text": "Topotecan is a topoisomerase I inhibitor which is currently evaluated as an adjuvant agent for malignant glioma.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 9], "name": "Topotecan", "tok_span": [0, 3], "new_tok_span": [1, 4]}, {"ent_type": "GENE", "char_span": [15, 30], "name": "topoisomerase I", "tok_span": [5, 9], "new_tok_span": [8, 12]}], "relation_list": [{"subject": "Topotecan", "sbj_char_span": [0, 9], "object": "topoisomerase I", "obj_char_span": [15, 30], "rel_type": "inhibitor", "sbj_tok_span": [0, 3], "obj_tok_span": [5, 9], "new_sbj_tok_span": [1, 4], "new_obj_tok_span": [8, 12]}], "umls_entity_list": [{"mention": "Topotecan", "char_span": [0, 9], "sem_type": "Pharmacologic Substance", "tok_span": [0, 3], "new_tok_span": [1, 4]}, {"mention": "topoisomerase I inhibitor", "char_span": [15, 40], "sem_type": "Pharmacologic Substance", "tok_span": [5, 10], "new_tok_span": [8, 13]}, {"mention": "adjuvant", "char_span": [76, 84], "sem_type": "Pharmacologic Substance", "tok_span": [16, 17], "new_tok_span": [21, 22]}], "new_text": "<START=Pharmacologic Substance> Topotecan <END=Pharmacologic Substance> is a <START=Pharmacologic Substance> topoisomerase I inhibitor <END=Pharmacologic Substance> which is currently evaluated as an <START=Pharmacologic Substance> adjuvant <END=Pharmacologic Substance> agent for malignant glioma."}, {"PMID": 15474503, "id": 4, "text": "Based on HMG-CoA reductase inhibition, pitavastatin-induced apoA-I more efficiently than simvastatin and atorvastatin.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [9, 16], "name": "HMG-CoA", "tok_span": [2, 7], "new_tok_span": [2, 7]}, {"ent_type": "CHEMICAL", "char_span": [39, 51], "name": "pitavastatin", "tok_span": [10, 14], "new_tok_span": [13, 17]}, {"ent_type": "CHEMICAL", "char_span": [89, 100], "name": "simvastatin", "tok_span": [23, 25], "new_tok_span": [29, 31]}, {"ent_type": "CHEMICAL", "char_span": [105, 117], "name": "atorvastatin", "tok_span": [26, 29], "new_tok_span": [32, 35]}, {"ent_type": "GENE", "char_span": [9, 26], "name": "HMG-CoA reductase", "tok_span": [2, 8], "new_tok_span": [2, 8]}, {"ent_type": "GENE", "char_span": [60, 66], "name": "apoA-I", "tok_span": [16, 20], "new_tok_span": [21, 25]}], "relation_list": [{"subject": "pitavastatin", "sbj_char_span": [39, 51], "object": "apoA-I", "obj_char_span": [60, 66], "rel_type": "regulator", "sbj_tok_span": [10, 14], "obj_tok_span": [16, 20], "new_sbj_tok_span": [13, 17], "new_obj_tok_span": [21, 25]}, {"subject": "simvastatin", "sbj_char_span": [89, 100], "object": "apoA-I", "obj_char_span": [60, 66], "rel_type": "regulator", "sbj_tok_span": [23, 25], "obj_tok_span": [16, 20], "new_sbj_tok_span": [29, 31], "new_obj_tok_span": [21, 25]}, {"subject": "atorvastatin", "sbj_char_span": [105, 117], "object": "apoA-I", "obj_char_span": [60, 66], "rel_type": "regulator", "sbj_tok_span": [26, 29], "obj_tok_span": [16, 20], "new_sbj_tok_span": [32, 35], "new_obj_tok_span": [21, 25]}], "umls_entity_list": [{"mention": "reductase", "char_span": [17, 26], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [7, 8], "new_tok_span": [8, 9]}, {"mention": "pitavastatin", "char_span": [39, 51], "sem_type": "Pharmacologic Substance", "tok_span": [10, 14], "new_tok_span": [13, 17]}, {"mention": "apoA-I", "char_span": [60, 66], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [16, 20], "new_tok_span": [21, 25]}], "new_text": "Based on HMG - CoA <START=Amino Acid, Peptide, or Protein> reductase <END=Amino Acid, Peptide, or Protein> inhibition, <START=Pharmacologic Substance> pitavastatin <END=Pharmacologic Substance> - induced <START=Amino Acid, Peptide, or Protein> apoA - I <END=Amino Acid, Peptide, or Protein> more efficiently than simvastatin and atorvastatin."}, {"PMID": 11161433, "id": 4, "text": "When the anti-corticosterone drug aminoglutethimide (CYP11A1 inhibitor) was administered to B16F10 mice, corticosterone levels in splenic tissue or serum and CYP11A1 mRNA expression were decreased at 14 days after tumor inoculation.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [34, 51], "name": "aminoglutethimide", "tok_span": [7, 11], "new_tok_span": [10, 14]}, {"ent_type": "CHEMICAL", "char_span": [105, 119], "name": "corticosterone", "tok_span": [27, 29], "new_tok_span": [34, 36]}, {"ent_type": "GENE", "char_span": [53, 60], "name": "CYP11A1", "tok_span": [12, 16], "new_tok_span": [17, 21]}, {"ent_type": "GENE", "char_span": [158, 165], "name": "CYP11A1", "tok_span": [36, 40], "new_tok_span": [45, 49]}], "relation_list": [{"subject": "aminoglutethimide", "sbj_char_span": [34, 51], "object": "CYP11A1", "obj_char_span": [53, 60], "rel_type": "inhibitor", "sbj_tok_span": [7, 11], "obj_tok_span": [12, 16], "new_sbj_tok_span": [10, 14], "new_obj_tok_span": [17, 21]}, {"subject": "aminoglutethimide", "sbj_char_span": [34, 51], "object": "CYP11A1", "obj_char_span": [158, 165], "rel_type": "regulator", "sbj_tok_span": [7, 11], "obj_tok_span": [36, 40], "new_sbj_tok_span": [10, 14], "new_obj_tok_span": [45, 49]}], "umls_entity_list": [{"mention": "corticosterone", "char_span": [14, 28], "sem_type": "Pharmacologic Substance", "tok_span": [4, 6], "new_tok_span": [5, 7]}, {"mention": "corticosterone", "char_span": [105, 119], "sem_type": "Pharmacologic Substance", "tok_span": [27, 29], "new_tok_span": [34, 36]}, {"mention": "aminoglutethimide", "char_span": [34, 51], "sem_type": "Pharmacologic Substance", "tok_span": [7, 11], "new_tok_span": [10, 14]}, {"mention": "CYP11A1", "char_span": [53, 60], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [12, 16], "new_tok_span": [17, 21]}, {"mention": "CYP11A1", "char_span": [158, 165], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [36, 40], "new_tok_span": [45, 49]}, {"mention": "tumor inoculation", "char_span": [214, 231], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [48, 50], "new_tok_span": [59, 61]}], "new_text": "When the anti - <START=Pharmacologic Substance> corticosterone <END=Pharmacologic Substance> drug <START=Pharmacologic Substance> aminoglutethimide <END=Pharmacologic Substance> ( <START=Amino Acid, Peptide, or Protein> CYP11A1 <END=Amino Acid, Peptide, or Protein> inhibitor ) was administered to B16F10 mice, <START=Pharmacologic Substance> corticosterone <END=Pharmacologic Substance> levels in splenic tissue or serum and <START=Amino Acid, Peptide, or Protein> CYP11A1 <END=Amino Acid, Peptide, or Protein> mRNA expression were decreased at 14 days after <START=Amino Acid, Peptide, or Protein> tumor inoculation <END=Amino Acid, Peptide, or Protein>."}, {"PMID": 9851542, "id": 1, "text": "The cardiovascular effects of three different acetylcholinesterase inhibitors: physostigmine, tacrine and rivastigmine injected by intravenous (i.v.) route were compared in freely moving Wistar rats.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [106, 118], "name": "rivastigmine", "tok_span": [19, 24], "new_tok_span": [21, 26]}, {"ent_type": "CHEMICAL", "char_span": [79, 92], "name": "physostigmine", "tok_span": [11, 15], "new_tok_span": [13, 17]}, {"ent_type": "CHEMICAL", "char_span": [94, 101], "name": "tacrine", "tok_span": [16, 18], "new_tok_span": [18, 20]}, {"ent_type": "GENE", "char_span": [46, 66], "name": "acetylcholinesterase", "tok_span": [6, 9], "new_tok_span": [7, 10]}], "relation_list": [{"subject": "physostigmine", "sbj_char_span": [79, 92], "object": "acetylcholinesterase", "obj_char_span": [46, 66], "rel_type": "inhibitor", "sbj_tok_span": [11, 15], "obj_tok_span": [6, 9], "new_sbj_tok_span": [13, 17], "new_obj_tok_span": [7, 10]}, {"subject": "tacrine", "sbj_char_span": [94, 101], "object": "acetylcholinesterase", "obj_char_span": [46, 66], "rel_type": "inhibitor", "sbj_tok_span": [16, 18], "obj_tok_span": [6, 9], "new_sbj_tok_span": [18, 20], "new_obj_tok_span": [7, 10]}, {"subject": "rivastigmine", "sbj_char_span": [106, 118], "object": "acetylcholinesterase", "obj_char_span": [46, 66], "rel_type": "inhibitor", "sbj_tok_span": [19, 24], "obj_tok_span": [6, 9], "new_sbj_tok_span": [21, 26], "new_obj_tok_span": [7, 10]}], "umls_entity_list": [{"mention": "acetylcholinesterase", "char_span": [46, 66], "sem_type": "Pharmacologic Substance", "tok_span": [6, 9], "new_tok_span": [7, 10]}], "new_text": "The cardiovascular effects of three different <START=Pharmacologic Substance> acetylcholinesterase <END=Pharmacologic Substance> inhibitors : physostigmine, tacrine and rivastigmine injected by intravenous ( i. v. ) route were compared in freely moving Wistar rats."}, {"PMID": 18081314, "id": 6, "text": "The bound conformation of U46619 fits the crystal structure of the PGIS substrate binding pocket considerably better than that of the unbound U46619.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [142, 148], "name": "U46619", "tok_span": [27, 31], "new_tok_span": [32, 36]}, {"ent_type": "CHEMICAL", "char_span": [26, 32], "name": "U46619", "tok_span": [4, 8], "new_tok_span": [5, 9]}, {"ent_type": "GENE", "char_span": [67, 71], "name": "PGIS", "tok_span": [14, 16], "new_tok_span": [17, 19]}], "relation_list": [{"subject": "U46619", "sbj_char_span": [26, 32], "object": "PGIS", "obj_char_span": [67, 71], "rel_type": "regulator", "sbj_tok_span": [4, 8], "obj_tok_span": [14, 16], "new_sbj_tok_span": [5, 9], "new_obj_tok_span": [17, 19]}], "umls_entity_list": [{"mention": "U46619", "char_span": [26, 32], "sem_type": "Pharmacologic Substance", "tok_span": [4, 8], "new_tok_span": [5, 9]}, {"mention": "U46619", "char_span": [142, 148], "sem_type": "Pharmacologic Substance", "tok_span": [27, 31], "new_tok_span": [32, 36]}, {"mention": "PGIS", "char_span": [67, 71], "sem_type": "Gene or Genome", "tok_span": [14, 16], "new_tok_span": [17, 19]}], "new_text": "The bound conformation of <START=Pharmacologic Substance> U46619 <END=Pharmacologic Substance> fits the crystal structure of the <START=Gene or Genome> PGIS <END=Gene or Genome> substrate binding pocket considerably better than that of the unbound <START=Pharmacologic Substance> U46619 <END=Pharmacologic Substance>."}, {"PMID": 12093311, "id": 3, "text": "This study was conducted in order to understand the association between acute renal failure and the two COX-2 inhibitors celecoxib and rofecoxib.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [121, 130], "name": "celecoxib", "tok_span": [21, 25], "new_tok_span": [22, 26]}, {"ent_type": "CHEMICAL", "char_span": [135, 144], "name": "rofecoxib", "tok_span": [26, 30], "new_tok_span": [28, 32]}, {"ent_type": "GENE", "char_span": [104, 109], "name": "COX-2", "tok_span": [17, 20], "new_tok_span": [17, 20]}], "relation_list": [{"subject": "celecoxib", "sbj_char_span": [121, 130], "object": "COX-2", "obj_char_span": [104, 109], "rel_type": "inhibitor", "sbj_tok_span": [21, 25], "obj_tok_span": [17, 20], "new_sbj_tok_span": [22, 26], "new_obj_tok_span": [17, 20]}, {"subject": "rofecoxib", "sbj_char_span": [135, 144], "object": "COX-2", "obj_char_span": [104, 109], "rel_type": "inhibitor", "sbj_tok_span": [26, 30], "obj_tok_span": [17, 20], "new_sbj_tok_span": [28, 32], "new_obj_tok_span": [17, 20]}], "umls_entity_list": [{"mention": "celecoxib", "char_span": [121, 130], "sem_type": "Pharmacologic Substance", "tok_span": [21, 25], "new_tok_span": [22, 26]}], "new_text": "This study was conducted in order to understand the association between acute renal failure and the two COX - 2 inhibitors <START=Pharmacologic Substance> celecoxib <END=Pharmacologic Substance> and rofecoxib."}]